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Multimodality Molecular Imaging of [
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Platinum based chemotherapy is amongst the mainstream DNA-damaging agents used in 
clinical cancer therapy today. Agents such as cisplatin, carboplatin are clinically 
prescribed for the treatment of solid tumors either as single agents, in combination, or as 
part of multi-modality treatment strategy. Despite the potent anti-tumor activity of these 
drugs, overall effectiveness is still hampered by inadequate delivery and retention of drug 
in tumor and unwanted normal tissue toxicity, induced by non-selective accumulation of 
drug in normal cells and tissues. Utilizing molecular imaging and nanoparticle 
technologies, this thesis aims to contribute to better understanding of how to improve the 
profile of platinum based therapy.  By developing a novel fluorinated derivative of 
carboplatin, incorporating a Flourine-18 (
18
F) moiety as an inherent part of the molecule, 
quantitative measures of drug concentration in tumors and normal tissues can be directly 
determined in vivo and within the intact individual environment. A potential impact of 
this knowledge will be helpful in predicting the overall response of individual patients to 
the treatment. Specifically, the aim of this project, therefore,  is  the development of a 
fluorinated carboplatin drug derivative with an inherent positron emission tomography 
(PET) imaging capability, so that the accumulation of the drug in the tumor and normal 
organs can be studied during the course of therapy . A secondary objective of this 
research is to develop a proof of concept for simultaneous imaging of a PET radiolabeled 
drug with a SPECT radiolabeled liposomal formulation, enabling thereby bi-modal 
imaging of drug and delivery vehicle in vivo. The approach is challenging because it 
involves development in PET radiochemistry, PET and SPECT imaging, drug liposomal 
encapsulation, and a dual-modal imaging of radiolabeled drug and radiolabeled vehicle. 
The principal development is the synthesis of fluorinated carboplatin 
19
F-FCP using 2-(5-
fluoro-pentyl)-2-methyl malonic acid as the labeling agent to coordinate with the 
cisplatin aqua complex. It was then used to treat various cell lines and compared with 
cisplatin and carboplatin at different concentrations ranging from 0.001 µM to 100 µM 
for 72 hrs and 96 hrs. IC50 values calculated from cell viability indicated that 
19
F-FCP is a 
more potent drug than Carboplatin. Manual radiosynthesis and characterization of [
18
F]-
FCP was performed using [
18
F]-2-(5-fluoro-pentyl)-2-methyl malonic acid with 
coordination with cisplatin aqua complex. Automated radiosynthesis of [
18
F]-FCP was 
 optimized using the manual synthetic procedures and using them as macros for the 
radiosynthesizer. [
18
F]-FCP was evaluated in vivo with detailed biodistribution studies 
and PET imaging in normal and KB 3-1 and KB 8-5 tumor xenograft bearing nude mice. 
The biodistribution studies and PET imaging of [
18
F]-FCP showed major uptake in 
kidneys which attributes to the renal clearance of radiotracer. In vivo plasma and urine 
stability demonstrated intact [
18
F]-FCP. [
111
In]-Labeled Liposomes was synthesized and 
physiochemical properties were assessed with DLS. [
111
In]-Labeled Liposome was 
evaluated in vivo with detailed pharmacokinetic studies and SPECT imaging. The 
biodistribution and ROI analysis from SPECT imaging showed the spleen and liver 
uptake of [
111
In]-Labeled Liposome and subsequent clearance of activity with time. [
18
F]-
FCP encapsulated [
111
In]-Labeled Liposome was developed and physiochemical 
properties were characterized with DLS. [
18
F]-FCP encapsulated [
111
In]-Labeled 
Liposome was used for in vivo dual tracer PET and SPECT imaging from the same 
nanoconstruct in KB 3-1 (sensitive) and COLO 205 (resistant) tumor xenograft bearing 
nude mice. PET imaging of [
18
F]-FCP in KB 3-1 (sensitive) and COLO 205 (resistant) 
tumor xenograft bearing nude mice was performed. Naked [
18
F]-FCP and [
18
F]-FCP 
encapsulated [
111
In]-Labeled Liposome showed different pharmacokinetic profiles. PET 
imaging of [
18
F]-FCP showed major uptake in kidneys and bladder. However, [
18
F]-FCP 
encapsulated [
111
In]-Labeled Liposome showed major uptake in RES in both PET and 
SPECT images. ROI analysis of SPECT image enabled by 
111
In corresponded with PET 
image enabled by 
18
F demonstrating the feasibility of dual tracer imaging from the single 
nanoconstruct. Future work involves the intensive in vitro characterization of [
18
F]-FCP 
encapsulated [
111
In]-Labeled Liposome and detailed in vivo evaluation of [
18
F]-FCP 
encapsulated [
111
In]-Labeled Liposome in various tumor models. 
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1.1 Rationale 
Platinum based anti-cancer therapy is a major treatment modality for various solid tumors 
in clinic. For many patients however, treatment efficacy is still hampered by normal 
tissue toxicity and drug resistance, which limits adequate dose in tumors. In order to 
better understand the extent of therapeutic efficacy, in relation to drug concentration, in 
vivo live imaging of tissue based drug pharmacokinetics is needed. Therefore, to reduce 
the adverse effect caused by platinum drugs, to increase the delivery, and to optimize the 
response of tumor, an approach of encapsulating the platinum drug inside the liposome 
and combining it with radioisotope would provide theranostic and synergistic effect. 
 
1.2 Objective 
The overall objective of this project is to develop a multimodal nanocarrier drug delivery 
system to investigate the delivery, retention and efficacy of anticancer therapy through 
molecular imaging. The aim of this thesis project is to develop a novel multimodal 
therapy/imaging paradigm, where a novel Fluorine-18 labeled Carboplatin derivative, 
cisdiammine{2-(5-[
18
F]-fluoropentyl)-2-methylmalonato-κ2,O,O’}platinum(II)},([18F]-
FCP) is encapsulated inside Indium-111 labeled liposome ([
111
In]-Labeled Liposome). 
The direction of this project is to combine the radiochemistry strengths that involve the 
ability to radiolabel organic molecules with 
18
F and other radioisotopes to perform 
Positron Emission Tomography (PET/CT) and Single Photon Emission Tomography 
(SPECT/CT) imaging in small animal with high spatial resolution, to study the 
biodistribution and pharmacokinetics of the pharmaceutical load of the nanocarrier. This 
proposal where the radiolabeled drug is incorporated inside the radiolabeled vehicle is 
quite novel which would be useful in evaluating the fate of drug by tracking the PET 
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signal from 
18
F, whether it stays with the nanocarrier by tracking the SPECT signal from 
111
In or is separated from the nanocarrier and is accumulated in tissues by looking at the 
dual tracer profile. The ultimate objective of this project is to provide a quantitative 
theranostic agent that is capable of relating the tumor drug availability to efficacy of drug 
delivery and treatment. These dual advantages from a single nanocarrier construct will 
eventually be translatable to the clinic for the diagnosis of solid tumor and metastasis and 
to effectively kill tumors. 
 
1.3 Statement of Aims 
The specific aims of the project are as follows: 
 
 To synthesize and characterize [111In]-Labeled Liposome nanocarrier to 
enable SPECT imaging. Labeling a nanocarrier allows to study the in vivo 
kinetic profile of the vehicle. Liposome, as a nanocarrier stays in the blood 
circulation for a longer period of time to deliver an effective dose to tumor via 
enhanced permeability and retention effect (EPR). Optimal SPECT agents with 
medium half life are required for extended imaging of the nano-vehicle.  
Therefore, for this project, the liposome was labeled with [
111
In] (t1/2 = 2.8 days, 
171 keV, 90%, and 245 keV, 94%) to determine the pharmacokinetic profile of 
the nanocarrier.  
 
 To synthesize and characterize [18F]-FCP as a theranostic drug for imaging 
and therapy. Our goal is to test the efficacy of drug in tumors.  This requires 
monitoring the drug’s therapeutic effectiveness in targeted site. Labeling the drug 
with 
18
F ( t1/2 = 110 mins,97% β
+
)  allows a pathway to determine the drug 
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metabolism, route of metabolism, clearance and tissue distribution in vivo. It 
provides a non-invasive imaging flexibility to assess the drug accumulation and 
retention in normal tissues and tumors using PET. 
 
 
 To encapsulate [18F]-FCP in [111In] - Labeled Liposome nanocarrier to enable 
two distinct SPECT and PET signals from one construct. Naked drugs once 
injected intravenously cause systemic toxicity due to non specific uptake. 
Encapsulation of drugs in nanocarrier reduces the exposure of drugs to normal 
tissue. This nanoconstruct (radiolabeled drug encapsulated in radiolabeled 
vehicle) provides in vivo data on fate of the drug, vehicle and the construct itself 
using multi-modal imaging.  In vivo information on accumulation and clearing 
profiles facilitates in optimizing the nanoconstruct for future targeted imaging and 
delivery. 
 
 To evaluate the doubly radiolabeled nanocarrier construct in tumor model 
using multimodal imaging. Determination of the behavior of the nanoconstruct 
in tumor is essential to determine the effectiveness of the delivery system. We 
evaluated our drug packaged liposomal carrier in tumor xenograft model. Dual 
tracer imaging using PET/SPECT was performed in nude mice inoculated with 
human epidermal cancer cell line KB 3-1 (Cervical Carcinoma) and COLO 205 
(Colon Carcinoma) to assess the in vivo pharmacokinetics of the nanoconstruct. 
1.4 Innovation 
 This work is innovative in two aspects: 
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 It proposes a novel dual modality guided imaging of a fluorinated drug 
encapsulated liposomal nanocarrier. Encapsulation of radiolabeled drug in 
radiolabeled vehicle will provide two distinct signals from one construct to study 
the overall pharmacokinetics of the drug and nanocarrier. This dual- modality 
imaging from one construct can offer synergistic advantages over a single 
modality. 
 Synthesis of [18F] - FCP as a novel theranostic anticancer drug for imaging and 
therapy. This project is innovative because it proposes a new approach to 
individualized therapy by “in situ” measurement of drug concentration, using 
molecular imaging, during the course of therapy. This technological advance of 
an image-guided platinum drug therapy has been enabled by developing the [
18
F] 
- FCP that retains very similar anti-tumor activity to the parent compound in 
various human cancer cell lines. This “drug biomarker”, could lead to how patient 
therapy can be individualized to affect the best possible response. 
 
1.5 Impact 
The impact of this work is tremendous in cancer imaging and therapy of platinum drugs. 
The proposed research will impact on how platinum drug therapy can be individually 
tailored to cancer patients, by directly monitoring drug treatment using PET imaging.  As 
of our knowledge, this is the first time that a platinum drug is labeled with 
18
F, a non 
invasive molecular imaging tracer for PET. The development of [
18
F]- FCP allows 
tracking and measuring the drug treatment and its accumulation in tumor and normal 
tissues during the course of therapy using non-invasive multimodal imaging. This 
capability provides a tool to identify responders from non-responders and will also help 
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to understand susceptibility or resistance to treatment.  Data from this project will provide 
direct measure of drug concentration in heterogeneous individual tumors in relation to 
response. Encapsulation of [
18
F] – FCP inside the liposome will also reduce the exposure 
of drug to normal tissue and hence reduce the normal tissue toxicity. In addition, 
encapsulation of drug inside the liposome will introduce favorable normal tissue 
pharmacokinetic profile compared to the naked drug and increases the tumor uptake of 
the drug by EPR effect and help in overcoming the tumor resistance 
 
1.6 Research Strategy/ Experimental Design  
This research developed a liposome platform (Fig. 1) for the delivery of anticancer agents. 
Liposomes with lipid shell radiolabeled with 
111
In were synthesized and were optimized 
for in vivo experiments. PEG modified phospholipids were used to provide a steric brush 
to minimize the lipid shell interactions from the blood components. Radiolabeled drug 
[
18
F]-FCP was encapsulated inside the [
111
In]-Labeled Liposomes. 
18
F is a positron 
emitter and has a potential for PET imaging to evaluate the in vivo kinetics of the drug. 
Carboplatin is water soluble that enables its encapsulation inside the liposome by using 
the hydration method or passive encapsulation method. 
111
In is a gamma emitter which 
enables SPECT imaging. Radiolabeling the shell with 
111
In helps to assess biodistribution 
and aim to follow the fate of the particle in vivo to obtain insights into the 
pharmacokinetics of the liposomes and to quantify the radioactive distribution in different 
tissues ex vivo. The liposome construct was evaluated in tumor xenograft model bearing 
nude mice. Biodistribution and imaging characteristics of encapsulated and free drug was 
determined in tumor bearing nude mice. Nude mice were inoculated with human 
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epidermal cancer cell lines to establish a xenograft model with one sensitive and one drug 
resistant tumor to assess the drug resistance and retention. 
 
 
 
Figure 1: Dual tracer labeled liposomal nanocarrier. [
18
F]-FCP encapsulated [
111
In]-Labeled 
Liposome was synthesized and was evaluated in tumor xenograft bearing mouse model. 
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2.1 Cancer  
Cancer is a disease caused by uncontrollable division of abnormal cells in a part of the 
body that has the potential to invade other tissues. Normal cells stop dividing when they 
come into contact with like cells by a mechanism known as contact inhibition. However, 
in cancer cells, genetic mutation in DNA affects the normal cell growth and division. As 
a result, cancer cells do not have normal checks and balances that control and limit the 
cell division (Fig. 2). Cell division for both normal and cancer cells is through cell cycle 
that goes from resting phase, through active growing phase and then to mitosis. The 
inability of cells to divide and copy itself in division results in cell death. Various cancer 
cell phenotypes such as cells with unlimited proliferative potential, environmental 
independence for growth, evasion of apoptosis, angiogenesis, altered metabolism, 
invasion and metastasis to different parts of body are the hallmarks of cancer [1, 2].  
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Figure 2: Cell division of normal and cancer cells 
    
 
Cancer is not one disease unlike many other local or organ specific diseases such as heart 
disease, kidney diseases etc. Cancer is a group of many diseases and is classified 
according to the fluid or tissue they initially originate from, or from the location in the 
body they are first developed. Pathologically, cancers are classified as below (Table 1). 
Table 1: Pathological classification of cancer 
 
Types                    Origin              Sub types 
Carcinoma • Epithelial cells in the skin or tissues that 
line or cover the internal organs 
• Adenocarcinoma 
• Squamous cell carcinoma 
• Basal cell carcinoma 
Sarcoma • Bone, cartilages, blood vessels, fat, 
muscles,  connective or supportive tissues 
• Osteosarcoma (bone) 
• Chondrosarcoma (cartilage) 
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Lymphoma • Originates in the cells of lymphatic 
system that develops in mature immune 
cells, mainly lymphocyte, spleen, thymus 
• Hodgkin’s lymphoma 
• Non-Hodgkin’s lymphoma 
Leukemia • Originates in hematopoietic cells 
residing in the bone marrow and blood 
• Acute myelogenous 
• Chronic myelogenous 
• Acute lymphocytic 
•Chronic lymphocytic 
 
Cancer refers to a group of conditions that manifests the malignant behavior and 
uncontrolled cell growth leading to invasion. Malignant cells have tendency to move 
from their site of origin and disseminate to distant organs and form metastases. This 
ability of malignant cells is aided by large number of characteristics they possess. 
Migrations, ability to invade stroma and endothelial linings, dissemination through 
circulation, survival are some of the underlying physiological and biological properties of 
solid tumors that allow them to grow in secondary sites. Epithelial solid tumors have 
proved to be a major challenge in cancer treatment. Treatment of solid tumors is based on 
the type, location and stage of the tumor. Complexity and non-homogeneity of solid 
tumors pose an obstacle in the delivery of an efficient amount of drugs to the cancer cells 
in a safe and effective manner. Streamlines of techniques have been proposed for the 
delivery of cancer drugs to solid tumors in search of more effective therapies. Local only 
therapies such as ablation, radiation have garnered positive responses. However, local 
therapy is always not feasible to treat solid tumors, especially the metastases. 
Several innovative approaches of delivering drugs into tumors using nanoparticles, 
liposomes, and micelles have been developed that can target tumor cells and help provide 
the information on the underlying biology of solid tumors. 
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2.2 Solid Tumors and Cancer Biology 
Tumors comprise of heterogeneous population of cells that, over time, develop means to 
sustain their growth and survival despite ongoing immune responses or therapies [3-5]. 
Malignant solid tumors arise after various phases of genetic changes, which endow them 
with resistant, proliferative, and invasive capabilities. Such phases include anaplasia (loss 
of structural differentiation), neoplasia (abnormal proliferation), dysplasia (change in 
tissue phenotype) and hyperplasia where increased proliferative rate of cells leads to 
excess of normal appearing cells. When cells further accumulate genetic changes leading 
to abnormal and disorganized tissue growth, the phase is referred as dysplasia. This phase 
is followed by carcinoma in situ where cells accumulate further mutations, continue 
anaplastic growth, but still be limited within basal lamina; hence preventing from 
metastases.  Further genetic insults result in malignant tumors, or often referred as cancer, 
cells increasingly become resistant to immune system or therapies and invade 
surrounding tissues or metastasize to distant organs [6, 7]. Metastases are often what 
cause death due to multiple organ failures in cancer patients. 
Various theories have been proposed as to how the tumor progression occurs. Although it 
is widely accepted now that the solid tumors are comprised of heterogeneous populations 
of cells, how the progression of tumor occurs had been debatable. Some of the theories 
proposed include linear progression model, multi/oligo-clonal progression model, and 
cancer stem cells and punctuated equilibrium model [8, 9]. Although linear progression 
model goes through the steps described above, it does little to explain the heterogeneity 
of the cells in the tumor mass. Oligoclonal progression model suggests that during 
progression of tumors leading to metastases, various populations of cells arise and coexist 
[8, 9]. Cancer stem cells and punctuated equilibrium model has garnered momentum as 
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of late. In many cases, patient relapse despite the optimal debulking and 
chemo/radiation/immune-therapies leading to no residual diseases. This has often 
attributed to the cancer stem cells, which are often thought to be more resistant and 
capable of giving rise to tumor cells [4, 8, 10, 11]. Stem cells have been described in 
various types of cancers including but not limited to breast, ovarian, and colon cancers 
[11-14]. They have been recognized to have increased resistance to chemo and radiation 
therapies and capable of inducing relapse and metastasis of tumors due to their 
regenerative capabilities. Presence of such cells limits the efficacy of traditional therapies. 
Hence, current studies have now started to take into account the importance of targeting 
such cell in the therapy regimen. Another phenomenon that often occurs during tumor 
progression is epithelial to mesenchymal transition (EMT) [15]. Although the causalities 
of this phenomenon in vivo is attributed to various growth factors and proteins such as 
TGF beta and EGF, many other factors are still being studied [15]. As of now, it has been 
clearly shown that EMT allows tumor cells of epithelial origin to be migratory through 
acquisition of mesenchymal phenotype and hence aid in metastases and disease severity 
by acquiring phenotypes like invasiveness and resistance to apoptosis [15, 16].  
Solid tumors are adept in resisting immunotherapies and chemotherapies by means such 
as abilities to survive in anoxic to hypoxic conditions, constant mutations and selection of 
antigen loss variants to evade immune system, and ability to resist the radiation and 
chemotherapies by certain cells such as cancer stem cells which constantly give rise to 
new cancer cells whilst helping progression and metastases [17-19]. Solid tumors pose 
many problems not only to ones’ immune system by a simple fact that most tumor 
antigens are self-antigens; hence immune system does not mount a robust response 
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against them. On top of that, solid tumors foster such an environment which poses 
difficulties to the therapies that are intended towards eliminating them. Most notable of 
such difficulties includes the delivery of the drugs. A precise dose and contained delivery 
of therapeutic agents limits the toxicities that are often associated with the cancer 
therapies. Recent advances in the field of nanoparticle delivery combined with radiation 
therapy have shown promising results in controlled delivery of drugs that are efficient in 
selectivity and cytotoxicity. Although these recent advances need to be validated via 
clinical trials before wide range of patients can benefit from them, progresses in such 
technologies are certainly promising.  
2.3 Imaging in Cancer Care 
Imaging plays an important role in the diagnosis of cancer. Biomedical imaging has many 
advantages including real time monitoring, accessibility without tissue destruction, 
minimal or non invasiveness and can function over wide ranges of time and size scales 
involved in biological and pathological processes [20]. Various multimodal biomedical 
imaging techniques are being used in all phases of cancer management. The goal of 
cancer imaging is to detect /and or image the smallest possible number of tumor cells, 
ideally before the angiogenesis switch [21, 22]. Major problems in cancer treatment are 
late diagnosis of cancer, lack of tools to visualize the treatment efficacy of the 
biological/chemotherapy treatment, absence of in vivo revelation of signaling pathways 
after radiation, chemo/biological therapy. Imaging provides a biological tool for the early 
detection of cancer, in vivo drug distribution, heterogeneity of tumor, and direct way of 
visualization of various pathways in vivo. Different metabolic pathways, cell proliferation, 
cell death and variety of disorders can be studied to a greater understanding using newly 
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emerged biomarkers and molecular imaging modalities which provides a better way of 
tailoring an effective treatment of the diseased sites. Molecular imaging modalities 
imaging the hall marks of cancer is further explained in Chapter 3. Medical imaging in 
cancer care is mainly aimed to determine how far a cancer has spread, guide delivery of 
specific treatments, and to predict the response of treatment. Imaging is widely employed 
in cancer care for various applications including staging, diagnosis, therapy response and 
image guided therapy/ surgery.  
    
2.4 Cancer Treatment and Therapy 
The treatment of cancer mainly depends on the type and stage of cancer, possible side 
effects of the treatment regimen, the patient’s preference and overall health of the patient 
itself. The multidisciplinary approach of treating cancer is very essential in determining 
the treatment option for the patient. The most common cancer treatments include surgery, 
radiation therapy, biological therapy, and chemotherapy. These therapies may be used 
alone, or in combination depending on the stage and sensitivity of cancer towards the 
treatment. Adjuvant and neoadjuvant therapies are also a major regime of cancer 
treatment. However, various other therapies are also looked upon for the treatment 
options such as targeted therapy, immunotherapy, hyperthermia, phototherapy, hormonal 
therapy, bone marrow transplantation etc. These therapies are not in the scope of this 
thesis and won’t be discussed in detail. Different types of cancer cells have unique 
properties that may not be readily treatable using the currently available cancer treatment 
procedure. Nanotechnology has emerged as a field with potentials to detect and treat 
cancer using nanoparticles. Motivation of using nanoparticles for cancer detection is 
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prompted from the ineffectiveness of currently available general treatment regimens, 
difficulty in early detection of tumors and numerous side effects.  
2.4.1 Surgery 
Surgery is the primary treatment for many cancers. Surgical resection can completely 
remove some cancers. However, it should be noted that surgery is a local treatment and it 
only treats the parts of the body it is operated on. So, if the cancer is on its early stage and 
is contained in one area, surgery may be the only treatment required to completely treat 
the tumor. However, if the cancer has spread to other parts of the body, surgery may not 
be the right treatment option. Surgery is used in clinic for various reasons. Diagnosing of 
cancer is done by a surgical procedure called biopsy, where a small piece of tissue is 
removed to test for the presence of cancer cells, type of cancer cells, and the rate of 
growth.  Surgery also reduces or prevents the risk of cancer. If a person is at high risk of 
particular type of cancer based on his/her family history/genetics, surgery may be able to 
reduce the risk of cancer. Woman with high risk of breast cancer may choose to have 
their breast removed.  Reconstruction surgery is another field of surgery in oncology 
which made it possible to recreate the part of the body that was resected using other body 
tissues. Breast reconstructions after mastectomy, bladder reconstruction after bladder 
removal are some of the usual reconstruction surgeries done in oncology.  Surgery is 
performed on the patients to remove or bypass blockage, to control pain caused by cancer 
that is pressing on a part of the body. Further, surgery may be used as a part of other 
treatments such as insertion of tube for chemotherapy, or biological therapy. 
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2.4.2 Radiation Therapy   
Radiation therapy is the use of high energy x-rays or other particles to kill cancer cells. 
Radiation therapy remains an important component of cancer treatment with 
approximately 50% of all cancer patients receiving radiation therapy during their course 
of illness; it contributes to 40% of curative treatment for cancer [23]. Radiation used in 
the treatment of cancer is ionizing radiation which forms electrically charged particles 
that deposit energy in the cells of the tissue it passes through. The deposition of energy 
results in the genetic changes (damages deoxyribonucleic acid, DNA) of cells resulting in 
cell death. DNA is the biological target of radiation. Radiation therapy kills cancer either 
by directly interacting with cellular DNA and causing death or by inducing free radicals 
from the excitation or ionization of the water component of the cells which causes 
indirect damage to DNA. Regardless of the mechanisms of cell kill, the major goal of 
radiation therapy is to deprive cancer cells of their proliferating potential and leading to 
cell death. Therapeutic efficacy of radiation is achieved by various cell death pathways 
(Fig. 3) 
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Figure 3: Types of cell death induced by radiation. Radiation mainly kills the cells either by apoptosis 
or mitotic catastrophe (adapted and modified from reference 
28
) 
 
Radiation can be used not only for treatment purposes but also for palliative treatment 
purposes to relieve patients from symptoms caused by cancer. Delivering radiation 
treatment can be accomplished either by using external beam radiation or by using 
internal beam radiation. External beam radiation delivers radiation treatment to cancer by 
aiming high energy rays from outside the body to the location of tumor. Internal beam 
radiation also known as brachytherapy delivers radiation treatment inside the body by 
using sealed radioactive sources or by sealed sources in catheters directly inserted into 
the tumor sites. Alike all cancer therapy, radiation therapy also aims to deliver as much 
dose to the tumor while sparing the normal tissues.  Various radiotherapy techniques have 
been emerged over the period of time that encompasses new imaging modalities, delivery 
systems with powerful computers and software in advancing the method of treatment and 
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improving the understanding of radiobiology and radiation therapy. Technological 
advances such as 3D conformal radiotherapy (3DCRT), Intensity modulated radiation 
therapy (IMRT), Image-guided radiation therapy (IGRT), Stereotactic radiosurgery (SRS), 
Stereotactic body radiation therapy (SBRT), Special procedures, Particle radiations 
(electron, proton, neutron beams) have improved the therapeutic ratio of radiation 
treatment. 
 
2.4.3 Biologically Targeted Therapy 
Spectacular progress in the field of cancer research unveiled the fundamental molecular 
basis of cancer progression. Differences in molecular biology, physiology, morphology, 
and pathways between the normal and malignant cells were well exploited which 
provided the insights on the behavior of cancer mechanisms and proliferation. Based on 
this knowledge, new biologically targeted therapeutic agents have been developed which 
specifically targets the gene expression and signaling pathways deregulated in the cancer 
cells. Cancer targeted therapies that use small molecules, peptides and antibodies have 
made therapy more specific to tumor sparing normal tissues [24]. 
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Figure 4: Schematics of targeted therapy of cancer that represents a new generation of drugs that are 
believed to interfere with the specific pathway of cancer to interfere with the growth of tumor 
progression (adapted and modified from reference 
24
) 
 
Some targeted therapies block specific enzymes and growth factor receptors involved in 
cancer cell proliferation. Targeted agents are categorized based on the mechanism of their 
action and the cells they target. Most of the targeted agents are small molecule drugs or 
monoclonal antibodies (mAbs). These agents perform their action either by inhibiting 
enzymes (tyrosine kinase inhibitors, preoteosome inhibitors, signal transduction 
inhibitors, growth factors inhibitors etc), by inducing apoptosis, or by inhibiting the 
angiogenesis pathways (Fig. 4). Presently, there are few hundred targeted cancer agents 
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in market including hundreds of new small molecule drugs and mAbs. Some of the 
selected targeted therapies in advanced clinical development are shown in Table 2 below. 
Table 2: FDA approved targeted therapies that interfere with variety of cellular processes. 
 
Biologically targeted agent Target (s) Indication (s) 
Bevacizumab (Avastin) VEGF  • Colorectal cancer 
• Glioblastoma  
• NSCLC 
• Renal carcinoma 
Cetuximab EGFR  • Squamous cell carcinoma of 
of head and neck 
• Colorectal cancer 
Gefitinib (Iressa) EGFR • NSCLC 
Imatinib (Gleevec) Tyrosine Kinases • GI stromal cancer 
•Systemic mastocytosis 
• Dermatofibrosarcoma  
protuberans 
Trastuzumab (Herceptin) HER-2 • Breast adenocarcinoma 
• Gastric adenocarcinoma 
 
Sorafenib (Nexavar) VEGF, Tyrosine Kinases • Advanced renal cell cancer 
• Hepatocellular carcinoma 
Dasatinib (Sprycel) Tyrosine Kinases (ABL) • CML 
• ALL 
Lapatinib (Tykerb) HER2, EGFR • Breast carcinoma 
 
2.4.4 Chemotherapy 
Despite the success in the development of various therapeutic innovations, chemotherapy 
is still a preferred method of therapy for a wide range of cancer [23, 25, 26]. 
Chemotherapy uses chemical substances that act electively on cells that are going through 
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mitotic cycle. The objective of chemotherapy in cancer is the selection of cytotoxic drugs 
and dose levels which predominantly is used in the treatment of metastases and 
dissemination without causing severe host toxicity. For the majority of solid tumors, 
chemotherapy is used to reduce the tumor volume and palliate symptoms. Most of the 
cases, chemotherapy has been used as an adjuvant to surgical and radiotherapy which 
results in the eradication of the subclinical metastases and leads to the prolongation of 
survival reducing the risk of recurrence. Chemotherapy can either be palliative or 
curative depending on the primary location and the extension of the disease. Depending 
upon the therapeutic scheme, chemotherapy can use a single therapeutic agent or a 
combination of substances. Primary tumors are heterogenic in nature and consist of 
metastatic potential, growth rate, immunogenicity, antigenecity and intrinsic response to 
cytotoxic drugs [26]. During the evolution stage of heterogenic tumors, some of them 
have favorable response to the cytotoxic agents while others do not. Therefore, for 
successful chemotherapy the drugs selected should be active when they are used alone, 
have known mechanism of actions and should not have toxicity grade higher than 
admissible grade. The maximal therapeutic effect is obtained with moderate drug toxicity 
and monitoring of the effects of the drug in the patient. However, the effect of 
chemotherapy is not strictly focused on cells or neoplastic tissues but have toxic action on 
the majority of normal cells especially on regions where normal physiological 
replacement of non-tumor cells occurs at a rapid rate. This results in the non-specific 
toxicity of cytotoxic agents. Wide ranges of chemotherapeutic agents (Table 3) are used 
in cancer care depending on the type of cancer and the mode of action of the 
antineoplastic agents. Chemotherapeutic agents act on metabolism and the 
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pharmacological and toxicological effect of cytotoxic agent depends on the drug 
concentration in the specific site of action. Thus the main aim of local delivery of 
cytotoxic agent to the disease site is to increase the local concentration in the specific 
area and minimize the exposure to the surrounding normal healthy cells. 
Table 3: Classification of chemotherapeutic agents used in cancer treatment 
 
Types of Agents         Target           Examples 
Platinum Coordinates • Binds with DNA  • Cisplatin, Carboplatin 
Oxaliplatin 
Antimicrotubules 
Agents 
• Binds with microtubules 
and stop mitosis 
• Taxanes  
(Paclitaxel,Docetaxel) 
• Vincaalkaloids 
(Vincristine, Vinblastine) 
Antimetabolites • Interfere with DNA and 
RNA  
• Damage cells during the S 
phase 
• Methotraxate 
• Fluropyrimidines  
(5-Fluorouracil, Capecitabine) 
• Gemcitabine 
Antitumor Antibiotics • DNA intercalation • Anthracyclines 
(Doxorubicin, Daunorubicin) 
• Camptothecins 
(irinotecan, topotecan) 
Alkylating Agents • Covalently bind to DNA • Cyclophosphamide 
• Nitrosoureas (Carmustine) 
•Alkane sulfonates 
   (Busulfan) 
 
2.4.4.1 Platinum Therapy 
Platinum based compounds such as cisplatin, carboplatin and oxaliplatin are widely used 
in clinic for the treatment of various malignancies. Since the accidental discovery of the 
biological properties of Cisplatin (cis-diamminedichloroplatinum (II) (Fig. 5)) in 1965 by 
Rosenberg et al, the era of platinum based anticancer therapy was introduced in clinic. 
Currently, cisplatin is one of the most commonly used anticancer drugs as a single agent, 
or in combination for the treatment of wide spectrum of malignancies such as testicular, 
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ovarian, bladder, cervical, head and neck, small cell and non small cell lung cancers [27]. 
However, cisplatin lacks tumor selectivity and the cumulative toxicities of cisplatin such 
as nephrotoxicity, ototoxicity, neurotoxicity, peripheral neuropathy limit the adequate 
dose administration [27-29]. Long term or high dose therapy may lead to severe anemia. 
To circumvent these adverse effects of cisplatin, several second and third generations 
platinum based drugs have been synthesized over the past few decades. Several of these 
second and third generation drugs are currently in clinical trials, however only few of 
these drugs were approved for use in humans. 
Carboplatin, (cis diammine-[1,1-cyclobutyldicarboxylato-(2)O,Oʹ] platinum (II)) (Fig. 5), 
is a second generation analogue of cisplatin. Carboplatin differs from cisplatin by having 
a cyclobutyldicarboxylato, a didentate ligand as the leaving group in place of two 
chlorides in cisplatin. Carboplatin is less toxic than cisplatin and exhibits antitumor 
activities to same types of tumors as cisplatin. As a result, carboplatin has replaced 
cisplatin in various treatment regimes in clinic. Owing to its reduced side effects, 
carboplatin is well tolerated by patients and can be used at higher doses than cisplatin 
[29]. Hearing loss and peripheral neuropathy are less common with carboplatin treatment, 
and nephrotoxicity is less as compared to cisplatin. However, visual changes or loss of 
vision has been reported with high doses of carboplatin and myelosuppression, 
principally thrombocytopenia is a dose limit factor for carboplatin [29, 30].  
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Figure 5: Chemical structure of platinum compounds; Cisplatin (A); Carboplatin (B); Oxaliplatin 
(C) 
 
The mode of action for cisplatin and carboplatin is similar. The principal biological target 
of platinum drugs is nuclear DNA. After the intravenous injection, cisplatin enters the 
cells via passive diffusion. In response to the lower chloride concentration inside the 
cytoplasm (20mM)  as compared to the serum (100mM), cisplatin undergoes activation 
by the aquation of one of two of its chloride leaving groups to form cis-
[Pt(NH3)2Cl(OH2)]
+
. This positively charged species is able to bind to the N7 position of 
purine bases, especially guanine to form either monofunctional or bifunctional adducts 
(Fig. 6) depending on the displacement of either one or two leaving groups [29, 31, 32]. 
Predominant binding occurs between two adjacent guanine based, forming 1.2 intrastnad 
cross links. These adduct cause distortions in the DNA double helix, and blocks 
replication and transcription of DNA helix. These distortions are eventually recognized 
by a number of cellular proteins that will ultimately trigger apoptotic cell death. 
Aquated species of carboplatin and cisplatin are same. However, the rate of aquation of 
carboplatin in phosphate buffer with a pH of 7 and at 37ºC is 100 folds slower than that 
for cisplatin [33]. 
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Figure 6: Cisplatin adduct formation and binding with DNA. The adducts formed by cisplatin and 
carboplatin are same. 
 
Oxaliplatin, cis-[(1R,2R)-1,2-Cyclohexane1,2-diamine]-[ethanedioato-O,O'] platinum(II) 
(Fig. 5) is another FDA approved drug which is known to treat cisplatin resistant tumors. 
Structurally, oxaliplatin differs from cisplatin by replacing two ammine ligands with 
(1R,2R)-cyclohexane- 1,2-diamine (R,R-dach). Due to this structural difference, the 
adducts formed by oxaliplatin differs from the DNA adducts formed by cisplatin and 
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carboplatin. The drug mainly forms GpG intrastand adducts with bulky hydrophobic dach 
ligand pointing into DNA major grove and preventing the binding of DNA [34]. 
Oxaliplatin is widely used in clinic for metastatic colon cancer as a single agent or as a 
combination therapy with 5-FU and folinic acid. 
The two other platinum based drugs that have been approved were nedaplatin and 
loboplatin. Nedaplatin, Diamine[hydroxyacetato 92-]O-Oʹ] platinum(II), is a second 
generation cisplatin analogue which is approved for the treatment of non-small cell lung 
cancer, esophageal cancer and head and neck cancers in Japan. Nedaplatin is more water 
soluble that cisplatin and possess similar anticancer properties as of cisplatin with lesser 
side effects [29]. 
Loboplatin, {[2-Hydroxypropanoato(2-)-O1,O2][1,2-cyclobutanedimethanamine-N-Nʹ]-
platinum(II), has been approved for the treatment of chronic myelogenous leukemia, 
inoperable metastatic breast cancer and small cell lung cancer in China. 
Thrombocytopenia is the most commonly observed dose limiting toxicity associated with 
loboplatin. 
2.4.4.2 Development of Platinum Analogues 
Motivation for the development of new platinum analogues prompted from the need to 
enhance the therapeutic index of the platinum drugs with reduced side effects and to 
increase their effectiveness against various platinum resistant tumors. Success of cisplatin 
triggered the intensive work on the discovery of new platinum based anticancer drugs. 
Cisplatin, Carboplatin, and Oxaliplatin are the first line platinum regimen for the 
treatment of various solid tumors. However, various other platinum analogues have been 
developed and tested in vivo for various solid tumors and platinum resistant tumors.  
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Orally administered JM216 (Satraplatin), sterically hindered ZD0473 (Picoplatin), 
ProLindac are three platinum analogues that are undergoing clinical trials in patients with 
refractory prostate cancer, small cell lung cancer respectively. Satraplatin is an orally 
active platinum drug that has shown antitumor activity against human lung, ovary, cervix, 
prostate and several platinum resistant tumors. Satraplatin is currently undergoing Phase 
I/II/III clinical trials in conjunction with various other anticancer drugs; docetaxel in the 
treatment of prostate cancer, paclitaxel in the treatment of NSCLC [35]. Picoplatin (cis-
Amminedichlorido(2-methylpyridine)platinum(II)) is a sterically hindered platinum 
analogue that has a pyridine ring perpendicular to the plane of platinum atom. In vitro 
study demonstrated the antitumor activity of picoplatin in cisplatin and carboplatin 
resistant tumor. Currently, picoplatin is in Phase I/II studies for colorectal cancer in 
combination with 5-FU and leucovorin, in conjunction with docetaxel for prostate 
carcinoma [36]. ProLindac is a nanopolymeric formulation of platinum drug, where the 
active moiety of oxaliplatin is bound to the hydrophilic biocompatible polymer 
(hydroxypropylmethacrylamide,HPMA) to improve the uptake through EPR effect. 
Treatment with ProLindac showed superior tumor growth inhibition with reduced side 
effect was observed in mice with B16 melanomas and ovarian carcinomas compared to 
oxaliplatin [36]. ProLindac in combination study with paclitaxel is currently in Phase II 
clinical trail in advanced ovarian carcinomas. Several other platinum analogues had 
undergone clinical trails but discontinued because of the lack of antitumor activity and 
because of their toxicity. The development of new and better platinum drugs is still a 
demanding area of research. Nanotechnology opens a plethora of opportunities in 
developing drug delivery vehicles for the delivery of platinum drugs that will alter the 
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biodistribution and pharmacokinetics of the drug and reduce the side effects, and enhance 
the therapeutic efficacy. Several nanoparticle formulations of platinum drugs are 
currently in clinical trials.  A key approach in cancer therapy research is to develop a 
drug delivery method that selectively delivers the drug to tumor site while reducing the 
toxicity to normal organs. Formulations of anticancer drugs with liposome have 
demonstrated significant reduction in side effect and altered pharmacokinetic profile that 
provides a unique opportunity to facilitate drug delivery to targeted sites. Therefore, this 
project utilizes liposomal drug delivery technology to engineer novel platinum drug 
formulation. 
 
2.4.4.3 Multidrug Resistance to Platinum 
Resistance to chemotherapy is a problematic aspect in the molecular biology of tumors 
and one of the most significant barriers in improving the effectiveness of cancer 
treatment [37]. Multiple drug resistance (MDR), both intrinsic and acquired, is a serious 
problem in solid cancers. There are several mechanisms by which cancer cells may 
express intrinsic resistance to platinum, such as, (i) impaired drug delivery, (ii) 
extracellular factors, (iii) decreased drug uptake into tumor cells, (iv) increased drug 
efflux, (v) drug inactivation by detoxifying factors, (vi) decreased drug activation or 
binding to target, (vii) altered target, (viii) increased damage repair, (ix) tolerance of 
damage (x) decreased proapoptotic factors, (xi) increased antiapoptotic factors, (xii) 
altered cell cycling and (xiii) altered transcription factors [38]. Moreover, different 
tumors in the same individual or even different cells within the same tumor may exhibit 
chemoresistance heterogeneity. The tumor cell interactions with host factors in the 
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humans constitute unique tumor microenvironment, which may contribute to 
chemoresistance [38].  
Resistance to platinum agents occur through various mechanisms including detoxification 
of platinum agents by glutathione or other anti-oxidants, decreased intracellular 
accumulation, increased DNA repair or DNA tolerance [38-41]. Platinum drugs enter the 
cells via passive diffusion down the concentration gradient. The facilitated transport of 
platinum drugs is enhanced by copper transporter-1 (CTR1) protein [39, 42-44]. Platinum 
resistant may be associated with the decreased CTR1 expression [45] in various cancers 
including lung cancer. Upon entering the cells, platinating drugs become aquated which 
interacts with DNA resulting cross-linking and inducing apoptotic cell death. 
Metallothiones and glutathione related metabolic enzymes such as glutathione transferase 
(GT) have a tendency to bind with the aquated platinum complexes and detoxify the 
platinum agents (Fig. 7).  
 
Figure 7: The mechanism by which tumor resistance to cisplatin and carboplatin occurs. Platinum 
drugs enter the cell through diffusion or by transporter, major being the copper transporters (CTR1). 
After the aquation of the platinum drugs, the activated aqua species preferentially reacts with species 
containing glutathiones of metallothioneins, mopping up the aquated species before DNA binding 
could occur (adapted and modified from reference
35
). 
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Elevated level of these sulfur containing compounds has been associated with resistance 
in lung cancer [38, 39, 42, 45]. ATP-binding cassette (ABC) super families of transport 
family proteins are associated with resistance in various cancers. The higher expression 
of copper transporter protein ATP7B is implicated to the chemoresistance of cisplatin in 
lung cancer[38, 41]. Breast cancer resistance protein (BCRP), a transporter and a member 
of ABC) was expressed significantly higher in chemo resistant patient treated for 
advanced non-small cell lung cancer NSCLC [41]. Higher expression of excision repair 
cross complementation group 1 (ERCC1), a form of DNA repair enzyme, has been 
shown to have chemoresistance effect in NSCLC[40, 45]. Subfamily C of ABC 
transporters includes multidrug resistance protein (MRP1-3) [46]. Higher expression of 
MRP is attributed to platinum resistance in small cell lung cancer (SCLC), NSCLC and 
other solid tumors [41, 47, 48]. However, there are several studies that are contradictory 
to the above and have failed to identify clear markers for chemoresistance in lung cancer. 
In an in vitro study, mRNA and protein expression levels of P-glycoprotein (MDR1), 
multidrug resistance-associated protein 1 (MRP1), and lung resistance-related protein 
(LRP) were investigated and compared with the chemosensitivity and the 
intracellular/intranuclear cisplatin accumulation of patient derived NSCLC cell lines 
(Ma-10, Ma-31, and Ma-46). The results of that study indicate that MDR proteins 
(MDR1, MRP1, and LRP) may not play an important role in the chemoresistance and 
drug efflux of platinum drugs in tumor cells [49].  
Despite the multifactorial nature of platinum resistance (Fig. 7), reduced intracellular 
drug accumulation is one of the most consistently identified features of cisplatin-resistant 
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cell lines [50, 51]. Furthermore, a recent clinical study established the relationship 
between tissue platinum concentration and response in NSCLC by analyzing tumor 
tissues excised from patients who received neoadjuvant platinum-based chemotherapy 
without radiation followed by curative surgical resection [52]. Earlier in 1988, platinum 
concentrations were determined in autopsy samples and found that the tumors of patients 
that responded to Cisplatin had higher mean tumor platinum concentrations than the 
tumors of patients that did not respond to Cisplatin [53]. These studies suggest that 
reduced platinum accumulation might be an important mechanism of platinum resistance 
and the tumor response to platinum based treatment appears to be directly related to drug 
concentrations in the tumor tissue in the clinical setting. However, there is no non 
invasive means of determining the concentration of platinum in normal tissues and 
tumors in patients. Concentration of platinum in tumors in patients is usually determined 
by adducts level in tumor biopsies using ICP. This invasive method of determining the 
platinum concentration is not feasible in cancer patients, especially when the tumor has 
metastasized. Therefore, this project aims in developing [
18
F]-FCP that will enable a 
quantitative non invasive imaging using PET that will ultimately provide a feasible way 
of determining the concentration of platinum in tissue basis. 
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CHAPTER 3: MOLECULAR IMAGING IN CANCER 
THERAPY 
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3.1 Molecular Imaging in Cancer Therapy 
Molecular imaging is an emerging medical discipline that can be defined as the fusion of 
visual representation, characterization, and quantification of biological processes at the 
cellular and sub-cellular levels within intact living organisms. This novel 
multidisciplinary field integrates cellular and molecular biology, medical physics, 
bioinformatics, biomathematics with diagnostic imaging techniques to produce a new 
imaging paradigm. Molecular imaging provides a platform that reflects cellular and 
molecular pathways and in vivo mechanisms of disease present within the context of 
physiologically authentic environments through the images produced using latest 
technological advancements. In the era of molecular medicine, the information on the 
complex biology of disease progression, drug metabolism and working therapies is 
crucial. Molecular imaging plays a pivotal role in understanding disease, in terms of 
biomarker diagnostics, early detection of disease, individualized treatment and potential 
prevention within the intact living subject. Molecular imaging detects not only the 
presence of the disease process, but can potentially also quantify its extent and severity, 
as well follow the course of disease over time [1]. Molecular imaging allows clinicians to 
detect the tumor location as well as to visualize the expression and activity of specific 
molecules and processes that influences the tumor behavior [2]. Traditionally, changes in 
tumor volume a general way of monitoring treatment response. However, singular 
measure of treatment response is not sufficient to predict the overall survival of the 
patient. Critical molecular features of neoplasm and its underlying pathophysiological 
mechanisms such as angiogenesis, metabolism, proliferation, and apoptosis can be 
- 38 - 
 
studied in details using molecular imaging probes that target those specific pathways (Fig. 
8) 
 
Figure 8: Molecular imaging probes and their cellular targets (reproduced from reference 
3
) 
 
 
Molecular imaging has the capacity to go beyond macroscopic imaging to noninvasively 
characterize biological process at the cellular and sub cellular level. Depending on the 
molecular tumor specificity, suitable molecular imaging modalities can be employed to 
study the biology. While several imaging modalities are employed to study physiologic 
and disease processes, response to therapy; radionuclide imaging stands out as the most 
commonly utilized imaging modality to exploit the molecular details.  
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3.2 Radiotracer Imaging 
 Imaging with radioisotopes allows obtaining the functional information unlike x-ray 
computed tomography (CT) which only provides the anatomical information. Radiotracer 
imaging employs radiotracers/radioligands that have the ability to interact with molecular 
targets involved in cancer. The development of imaging modalities such as PET and 
single photon emission tomography SPECT allows the in vivo visualization of biological 
processes at the molecular and cellular level. Both of these imaging modalities involve 
the use of exogenous radioactive nuclides injected intravenously to obtain an image of 
the distribution within the body after administration. This project focuses on SPECT and 
PET which are further detailed in the sections below. 
 
3.2.1 Single Photon Emission Tomography 
Single photon emission computed tomography, commonly known as SPECT is an 
imaging technique in nuclear medicine. It is very similar to the conventional planar 
imaging using a gamma camera. The fundamental basis for SPECT imaging is the 
detection of monoenergetically emitted γ-rays from intravenously injected exogenous 
SPECT radionuclides (Table 4). 
 
Table 4: Commonly used single photon emitting radionuclides 
 
Nuclides Half Life Emission Energy Mode of Decay 
111
In 2.80 days 171, 245 keV EC (100%) 
99m
Tc 6.02 h 142 keV IT (100%) 
123
I 13.22h 159 keV EC (100%) 
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131
I
 
8.03 days 364 keV β- (100%) 
EC: Electron Conversion, IT: isomeric transition, β-: beta-minus 
Basically, when a SPECT radioisotope decays, one or more γ-rays having particular 
energies are emitted in random directions from within the subject after the radiotracer 
injection. These γ-rays pass through a multichannel lead collimator (parallel hole or pin 
hole in order to give access to give the best spatial resolution/sensitivity/FOV) which 
restricts the view of the detector to those events originating form the area to be imaged.  
Optimal window is selected based on the direction of the photons reducing the detection 
of scattered photons. The selected photons traveling along single line of response 
corresponding to the individual aperture in the collimators are detected by sodium iodide 
(NaI) crystal. The crystal after the detection of the photons emits light which is amplified 
by photomultiplier tubes and is recorded. The gamma detector in SPECT rotates around 
the subject to detect the emissions. 2D images would be acquired by rotating the gamma 
camera at different angles. The acquired 2D image set is converted to 3D image data 
using tomographic reconstruction algorithm (Fig. 9).  
  
   
Figure 9: Schematic representation of SPECT System 
   
SPECT is a rapidly changing field and various areas of research in the development of 
new hardware and image processing algorithms is being carried out. The use of longer 
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lived half life radionuclide and lower cot of gamma cameras make SPECT imaging 
widely available for pre clinical and clinical use. SPECT benefits from longer half lives 
radioisotopes that enable imaging studies to be conducted over longer period of time.  
Recent advancements on nanotechnology further advanced the field of molecular imaging 
with radiolabeled nanoparticles. Extrinsically or intrinsically radiolabeled nanoparticles 
with targeting moieties can interrogate specific molecular and cellular events in living 
organisms. 
111
In-Quantum dots, 
125
I labeled single walled carbon nanotubes, 
111
In labeled 
monoclonal antibodies linked iron oxide nanoparticles are some of the examples of 
nanoparticles used for SPECT imaging in pre clinical animal models [4]. The major 
advantage of SPECT is superior spatial resolution and it can potentially allow for 
simultaneous imaging of multiple radionuclides. However, for a given size of detector 
and FOV, SPECT suffers from tradeoff between resolution and sensitivity [5, 6]. Recent 
advances on the development of cadmium zinc telluride (CdZnT) direct conversion 
detectors allow higher intrinsic resolution and effectively eliminates the dead space at the 
edges of detectors [5, 7, 8]. Recent advances in iterative reconstruction algorithms 
provide the flexibility and versatility to SPECT imaging. 
3.2.2 Positron Emission Tomography 
Positron Emission Tomography, commonly known as PET imaging is a widely used 
molecular imaging modality which provides 3D image of functional processes in the 
body.  PET scanner consists of full detector ring with hundreds of coincidence coupled 
detectors. After the administration of positron emitting radionuclide (Table 5), there 
would be a tracer uptake by different organs.   
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Table 5: Commonly used positron emitting radionuclides 
 
Nuclides Half Life Max. Energy/MeV Mode of Decay 
18
F 110 min 0.64 β+ 
11
C 20.3 min 0.97 β+ 
13
N 10 min 1.20 β+ 
15
O 2 min 1.74 β+ 
64
Cu 12.7 h 0.66 β+/EC 
68
Ga 68.1 min 1.90 β+/EC 
76
Br 16.2 h 4.00 β+/EC 
124
I 4.18 days 2.14 β+/EC 
β+: beta- plus; EC: Electron Conversion 
The tracer decay naturally producing a positron (positive electron) which travels a certain 
distance (depending on its energy) and interacts with a free or loosely bound negative 
electron. This annihilation of one positive and one negative electron with each other 
results in their masses being converted into two photons, consisting of 511 keV energy 
being given off at approximately 180º to each other (Fig 10). After the detection of one 
photon by a detector, a small amount of light is produced that is amplified as an electrical 
signal and is detected as a single count. After this detection, the system waits for another 
single count to occur in another detector. If these two single counts occur in the 
prescribed time interval, these photons are paired together and stored as a coincident 
event (true detection, Fig. 10). This detected coincident event signifies that annihilation 
occurred along the line connecting the two detectors referred to as line of response (LOR). 
The integrals of annihilations event is measured along the LOR and is stored in a 2D 
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matrix called sonogram. Tomographic reconstruction methods such as filtered back 
projection (FBP) and ordered subsets expectation maximization (OSEM) are employed to 
reconstruct images from sonogram data [9].  
 
Figure 10: Principle of PET imaging: positron emitting radionuclide yields a positron that travels a 
short distance and annihilates with an electron and produce two collinear 511 keV photons. These 
photons exit the body and are detected by an array of scintillation crystals 
 
However, there is a probability of scatter or attenuation of the annihilated gamma rays 
before exiting the body because of their interaction with the tissues. If one or both of the 
γ-rays undergoes compton scattering before reaching the detector, the direction of the 
photon is likely to change and the scanner could incorrectly position the resulting 
coincidence event to wrong LOR (Fig. 11). Scattered coincidence event adds statistical 
noise to the signal. Random coincidence events (Fig. 11) are caused by the incorrect 
pairing of the two photons arising from different annihilations within the coincidence 
window of the detectors. Likely caused by the attenuation of one of the photons, or 
lacking of detection of photon by the system, random coincidence adds noise to PET 
image [6]. 
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Figure 11: Depiction of the non-colinearity of the annihilation photons; scattered coincidence occurs 
when one or both of the photons are scattered but are still detected in the same energy and 
coincidence window in the detector (A); random coincidence occurs when two photons arising from 
coincidence window in the detector (A); random coincidence occurs when two photons arising from 
two different annihilation events are detected in the same coincidence window (B) 
 
 
Owing to the high resolution, high sensitivity instrumentation for γ- ray detection and 
unlimited tissue penetration, interest in in vivo imaging using PET is growing. Positron 
emitting radiotracers are primarily used to tag small molecules that are recognized by 
enzymes or bind to receptors and other targets [10]. As a result, numerous PET 
radiotracers have been developed for a wide range of applications (Table 6). 
 
Table 6: Commonly used PET radiopharmaceuticals (adapted from reference 
18
) 
 
PET Probe Application Mechanism 
[F-18] fluorodeoxyglucose Glucose Metabolism 
 
Accumulation as  
sugar phosphate 
[F-18] fluoride Bone Scanning Incorporation into bone 
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[F-18] fluoromisonidazole Hypoxia Redox indicator 
[F-18] fluorothymidine Proliferation Incorporation into DNA 
[C-11] acetate Fatty acid oxidation Uptake and clearance by fatty 
acid 
[C-11] choline Protein metabolism Incorporation into phospholipids 
 
3.3 Molecular Imaging in Image Guided Therapy 
Morphological imaging with an assessment of the biological function and metabolism is 
an invaluable tool for assessing the overall success of the treatment. Image guided 
therapy uses imaging techniques to aid in providing localization and targeting of diseased 
tissue, visualizing the extent of malignancies and particularly helps in specificity and 
identifying cancer. Image guided surgeries and minimally invasive interventions emerged 
over the past few decades replaced the traditional invasive approaches and helped in 
monitoring and controlling treatments. In modern medicine, nuclear medicine imaging 
techniques such as PET/SPECT, advanced imaging technologies such as MRI, CT 
entered into interventional and surgery suites to complement on the already available 
imaging techniques such as X-ray and ultrasound. Molecular imaging guided surgeries; 
MRI guided focused ultrasound surgeries, recently developed intraoperative imaging 
techniques substantially increased the versatility of modern interventional system and 
accelerated the process of image guided therapy. Integrated PET-MR promised a new 
avenue in radiation oncology for dose planning and therapy owing to the properties like 
superior resolution, soft tissue contrast and multi-planar capabilities. An ongoing clinical 
trail is using [
18
F]-FMISO dynamic PET-CT and functional MRI for imaging tumor 
hypoxia in locally advanced unresectable non-small cell lung carcinoma [1]. Further 
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work on using CT-MR on verifying the delivery of planned dose to the clinical target 
volume in prostate cancer, assessing the dose to the organs at risk are some of the 
connections between MR diagnostics and dose planning system in radiotherapy which 
highlights the use of molecular imaging in image guided therapy [11]. 
3.3.1 Molecular Imaging in Staging and Tumor Expression 
Molecular imaging can improve all aspects of clinical cancer care [12]. Application of 
PET-CT in oncology has substantially influenced the management of cancer patients. 
PET-CT has the ability to generate morphological and anatomical information in a single 
examination that will provide an efficient and accurate approach on tumor staging. FDG-
PET imaging takes advantage of alterations in glucose metabolism, which is a hall mark 
of cancer. Prospective studies have shown the higher sensitivity and specificity of this  
imaging principle [12]. Therefore, FDG-PET has high accuracy for staging of various 
solid tumors and is intensively used in clinic widely. Several new PET tracers have 
emerged that can improve the staging of cancer using PET. 
11
C-choline PET has very 
high specificity and sensitivity for staging and restaging of prostate cancer. Many studies 
have evaluated whole body-diffusion weighted imaging (WB-DWI) as a potential 
alternative for the detection of metastatic lesion. Tumor metabolism study using 
conventional MRI/MRS may serve as a predictive marker for prostate cancer. 
Molecular PET imaging plays a pivotal role in identification and quantification of 
specific targets and receptor expression in vivo. Various new imaging probes employed in 
nuclear imaging have proven to be useful in detecting the presence of various targets due 
to the consequence of drug target interaction. 
11
C-raclopride for dopamine D2 receptors 
and 
125
I-SD7015 for cannabinoid receptor are two of the many examples of imaging drug 
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probe used to obtain qualitative and quantitative data in the tumors of central nervous 
system[13]. 
64
Cu-VEGF in PET imaging is another approach of an imaging probe that 
directly interacts with the target. Vascular endothelial growth factor receptor (VEGFR) is 
associated with tumor angiogenesis. 
64
Cu-VEGF directly binds to VEGFR and PET 
imaging of 
64
Cu-VEGF helps in assessing the tumor target expression. However, 
synthesizing a new customized imaging probe needs individual characterization for 
specificity and sensitivity and is costly and time consuming. Reporter gene imaging 
provides an alternative to direct target imaging. Several approaches have been emerged to 
encode reporter gene with specific enzymes or for receptor capable of binding the 
radioactive ligand. Using molecular imaging techniques such as MRI/ MRS, optical or 
radionuclide imaging, reporter genes help in the evaluation of level of expression of 
specific genes, receptor activities and protein-protein interactions [14]. 
3.3.2 Tumor Metabolism Imaging  
High specific and sensitive imaging of increased metabolic rates for glucose, amino acids, 
or lipids associated with malignant tissues have led to a remarkable success of tumor 
metabolism imaging in recent years. PET imaging with glucose analog, [
18
F]-FDG, is the 
most commonly used imaging technique to study glucose metabolism of cancer cells in 
vivo. After intravenous injection, [
18
F]-FDG is recognized and is transported across the 
cell membrane by sodium independent glucose transporters mainly Glut-1, Glut-3 which 
is phosphorylated by hexokinase to form [
18
F]-FDG-6-phosphate. FDG-6-phosphate is 
not a substrate for glycolysis and cannot go further glycolytic pathway because of the 
fluorine atom at the C2 position prevents [
18
F]-FDG-6-phosphate from further 
degradation. As a result, the metabolite gets trapped within the tumor cells which is 
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exploited for tumor metabolism imaging by PET imaging [15]. PET imaging using [
18
F]-
FDG has been used as an indicator of therapy response. PET imaging of FDG takes 
advantage of one of the hall mark of cancer, namely the Warburg effect; increased 
glucose metabolism and conversion of glucose carbon to lactate are the characteristics of 
cancer cells as compared to normal cells [12]. This characteristics of malignant cells is 
attributed to the overexpression and increased activity of glucose transporters in the cell 
membrane of malignant cells [16].   However, specificity of [
18
F]-FDG still remains. 
After the therapeutic intervention, tumors usually show inflammatory responses leading 
to a transient increase in glucose metabolism. [
18
F]-FDG also accumulates in non-cancer 
tissues (usually tissues with high metabolic activity such as inflammatory lesions, brain, 
heart) and the interpretation of the imaging signal may be confounded by metabolic flare 
phenomena [17]. 
Various other alterations such as changes in amino-acid transport, protein synthesis, 
including the overexpression of cholin kinase (ChoK) is observed in malignant tumors. 
Complementary information on tumor biology is further useful for the diagnosis and 
therapy monitoring of tumors. Non-selective uptake of [
18
F]-FDG lead to efforts to 
establish amino acids based tracers for tumor metabolism imaging (Fig. 12). Tumor cells 
have increased amino acid transport. 
11
C-labeled and 
18
F labeled amino acids such as 
methionines, tyrosines, and methyltyrosines are widely used for accurate metabolic 
cancer imaging [17]. Tracers were mainly used in brain tumors in which they showed 
excellent contrast between normal brain and tumors and exhibited higher sensitivity in 
tumor detection. Therefore, amino acids have the probable advantage over FDG in the 
imaging of brain tumors since the background tracer accumulation is lower as compared 
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to FDG. Although amino acids have a potential in differentiating between inflammation 
and malignancy, various studies have suggested that uptake of amino acid might occur in 
benign regions such as ischemic brain, infarction, scar and in irradiated studies [15]. 
Therefore, monitoring of treatment response of tumor using amino acid must be validated 
with further studies. 
Phosphocholine is the most abundant phospholipid found in the cell membrane. Elevated 
level of phophocholine have been detected by various spectroscopic studies in variety of 
tumors, including breast, prostate and brain tumors [18]. Imaging approach based on the 
increased need of cancer cells for the cell membrane component phosphatidylcholine, 
increased transport and phosphorylation of choline lead to synthesis and pre clinical and 
clinical evaluation of choline based tracers. Radiolabeled choline and choline analogs 
(
11
C-choline, [
18
F]-choline, [
18
F]-fluoroehtylcholine) have been used to study tumor lipid 
metabolism by PET and have shown rapid accumulation in variety of human cancers 
including prostate, gliomas, non small-cell lung cancer and esophageal cancer [19]. 
Recent studies have also shown the avid uptake of 
11
C-acetate in various malignancies. 
Studies on the uptake of 
11
C-acetate correlated the uptake with the fatty acid synthase 
expression levels in cancer cells and attributed the observation to the anabolic pathway 
which uses acetate for synthesis of fatty acids and lipids [19]. 
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Figure 12: Overview of metabolic processes targeted by PET and MRI in the study of tumor 
metabolism study (adapted and modified from reference
10
) 
 
 
3.3.3 Tumor Proliferation Imaging 
Abnormal cellular proliferation is a hall mark of cancer. Imaging and measuring 
proliferation is a potentially broad and specific target for the assessment of tumor 
progression and response to therapy. DNA synthesis is the most directly related 
metabolic process to cell division. Most of the non-invasive methods of imaging the cell 
proliferation have focused on the thymidine (TdR) salvage pathway of DNA synthesis 
because TdR contains the only pyrimidine or purine base that is unique to DNA [20].  
11
C-thymidine, which was used for detecting tumors and for the assessment of therapy, 
was limited by the short half life and rapid catabolism of TdR upon injection. Several 
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analogs of TdR have been radiolabeled with isotopes for imaging tumor proliferation. 
However, the most studied TdR analogs till this point are 
18
F-labeled- 
3ʹ-deoxyfluorothymidine ([18F]-FLT) and 18F-1-(2ʹ-deoxy-2ʹ-fluoro-β-D-
arabinofuranosyl) thymine ([
18
F]-FMAU).  
Insight on the pharmacokinetics of [
18
F]-FLT indicates the prospective assessment of 
disease response and identification of rapidly proliferating tumor cells. [
18
F]-FLT PET 
provides the data on the activity of thymidine kinase (TK) activity. After injection, [
18
F]-
FLT enters the cell and is phosphorylated by thymidine kinase 1(TK1) to [
18
F]-FLT-
monophosphate [21]. Additional kinases act on [
18
F]-FLT-monophosphate and convert 
[
18
F]-FLT-monophosphate to diphosphate and triphosphate (Fig. 13).  Replacement of 
hydroxyl group at the 5ʹ position (Fig. 13) of deoxyribose prevents [18F]-FLT- 
triphosphate from cleavage by thymidine phosphorylase and from incorporating into 
DNA therefore making it as a substrate for TK1. This phosphorylation makes [
18
F]-FLT 
too polar to exit the cell via membrane and hence gets trapped in the cell. Since, TK1 
(cytosol) is a key enzyme in the DNA synthesis through the salvage pathway in cell, the 
degree of accumulation of [
18
F]-FLT behaves as a biomarker for proliferation.  
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Figure 13: Thymidine salvage and de novo synthesis pathway. [
18
F]-FLT is transported into the cells 
and phosphorylated to [
18
F]-FLT monophosphate ([18F]-FLTMP) which can be further 
phosphorylated to diphosphate and triphosphate. However, due to the substitution of OH with 
18
F in 
5-position, [
18
F]-FLT is not incorporated into the DNA. (adapted and modified from reference 
14
) 
 
 
[
18
F]-FMAU has been developed for proliferation imaging with labeling at 2ʹ-fluoro 
position of the sugar with 
18
F (Fig. 14). Preliminary clinical studies have shown that the 
accumulation of [
18
F]-FMAU in tumors comparable to that seen in human studies with 
[
18
F]-FLT [20]. [
18
F]-FMAU, having a 3ʹ-hydroxyl group acts as a substrate for 
thymidine kinase 2 (TK2) in mitochondria and gets incorporated into DNA. However, the 
primary limitation of [
18
F]-FMAU is that it appears to be the poor substrate for cytosolic 
TK1. Cytosolic TK1 is dependent on cell cycle with higher expression during S, G2, M 
phases in dividing cells. Mitochondrial TK2 expression is independent of cell cycle. 
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Therefore, the visualization of TK2 activity using [
18
F]-FMAU with PET imaging may be 
less accurate index of cell proliferation [22]. [
18
F]-FLT PET provides data on TK1 
activity and [
18
F]-FMAU provides data on TK2 activity. TK1 and TK2 are independent 
enzymes and the information received wit changes in [
18
F]-FLT and [
18
F]-FMAU 
respectively provides different biological information on cell proliferation and 
mitochondrial mass in tissue. Therapeutic regimen using cytotoxic agent changed the TK 
activity. Hence, the biological effect of therapy on [
18
F]-FLT and [
18
F]-FMAU 
accumulation and its implication must be validated further with scientific discussion [22]. 
   
Figure 14: Chemical Structure of (A) [18F]-FLT; (B) [18F]-FMAU 
     
3.3.4 Cell Death Imaging 
Cell death imaging plays an important role in detecting the onset of cell death in tumor. 
Cell death is an essential biological and pathological process in an organism that is 
critical for the correct formation of organs and tissue development. Cell death is hall 
mark of various pathological conditions including cancer. Imaging that can locate and 
identify cell death will greatly increase the understanding of cell death and its 
implications on diseases and therapeutic responses. Currently, there is no probe that has 
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been approved for routine cell death imaging in clinic. Various cell death biomarkers and 
probes have been developed exploiting various cellular events (Fig. 15) and tested in vivo. 
Few of the imaging probes reached clinical trials but failed. The major challenges in 
developing a cell death imaging agent include the choice of a relevant molecular target, 
the accurate detection of the temporal and spatial occurrence of cell death, optimization 
of probe pharmacokinetics, and the minimization of non specific tissue binding and 
maximization of tissue contrast [23].  
 
Figure 15: Cellular events that have been exploited for imaging cell death (adapted and modified 
from reference
 16
) 
 
Annexin-V(AnxV) is the most widely used probe for phosphatidylserine-based detection 
of apoptosis that has reached phase III clinical trial. AnxV forms trimer-based lattices on 
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the surface of apoptic cells, inducing strong cooperative phosphatidylserine binding and 
driving cellular internalization. Despite its early promise for detecting apoptosis, AnxV 
showed suboptimal pharmacokinetic profile and non specific binding to tissues[24]. 
Synaptotagmin-I (SynI) is a synaptic-vesicle associated membrane protein that contains 
C2A and C2B domain and is responsible for Ca
2+
 dependent binding to 
phosphatidylserine and phosphatidylinositol. Approaches on radiolabeling the C2A 
domain with 
99m
Tc or 
18
F for visualizing cell death in animal model resulted in 
heterogenous probe mixtures. Reccent studies on fluorescently labeling that C2Am 
domain had better specificity for detection of apoptosis and necrosis [25]. 
18
F-ML-10, a 
PET based tracer was introduced as small molecule agent capable of detecting the plasma 
membrane depolarization and acidification of the apoptotic cell [24, 26]. Assessment of 
correlation of early changes after radiation therapy using 18F-ML-10 in various solid 
tumors is currently taking place [23]. Uptake of Caspase-3/-7specific PET radiotracer 
18
F-ICMT-11 ((
18
F-(S)-1-((1-(2-fluoroethyl)-1H-[1,2,3]-triazol-4-yl)methyl)-5-(2(2,4-
difluorophenoxymethyl)- pyrrolidine-1-sulfonyl)isatin) after drug treatment was almost 
double, predicting the early detection of drug induced tumor apoptosis in xenograft 
models of lymphoma [27]. Structurally well defined probe development and its clinical 
translation for simultaneous imaging of cell death will help clinicians diagnose onset of 
diseases and tailor individualized treatment options. 
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CHAPTER 4: NANOPARTICLE DELIVERY OF ANTI-
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4.1 Drug Delivery Systems 
The effectiveness of anticancer therapy depends on adequate delivery of therapeutic 
agents and enhanced retention in solid tumors. Conventional chemotherapy drugs suffer 
from lack of selectivity hence they cause significant damage to the normal proliferating 
cells of tissues and organs. In addition, some mainstream drugs also suffer from limited 
aqueous solubility and require solvent formulations that contribute to toxicity (e.g. 
paclitaxel formulation in Cremophor oil). The poor efficacy is further exacerbated by   
increased drug efflux due to activation of transmembrane protein efflux pumps, such as 
Pgp, MRP, BCRP etc. and detoxification by glutathione; resulting in less drug retention, 
and ultimately leading to drug resistance.  Tools to address some of these problems 
require rationale approaches to quantitatively measure tumor and normal tissue 
concentrations of systemically administered drugs.   Advancements in the development of 
nanoscale drug delivery vehicles, with distinct physical and biochemical properties for 
delivery applications, have the potential to improve the therapeutic index of currently 
available drugs by increasing the drug efficacy. Examples of these nano-carriers include 
nanoparticles, such as polymers, inorganic molecules, microbubbles, micelles, 
dendrimers, and liposomes. Platinum drugs are a major class of anticancer drugs in clinic. 
However the treatment efficacy of platinum drugs is hampered by multidrug resistance 
and increased normal tissue toxicity. This thesis project exploits the field of 
nanotechnology and introduces radiolabeled liposome ([
111
In]-Labeled Liposomes) as a 
drug delivery vehicle for novel fluorinated carboplatin derivative to study the 
pharmacokinetics and efficacy of liposomal platinum. 
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4.2 Nanoparticles in Drug Delivery 
Colloidal particles with size ranging between 1 to 100 nm are known as nanoparticles [1, 
2]. Nanoparticles have emerged as a promising approach to overcome the delivery 
barriers in solid tumors and specificity limitations of conventional drugs. Various types 
of nanoparticles based on metals, lipids, polymers and biological nanoparticles have been 
investigated for drug delivery systems. Each of these nanoparticles has its own 
advantages and disadvantages depending on its application. A brief comparison of these 
nanoparticles on drug delivery application is shown in Table 7. Nanoparticles have the 
potential to reduce drug toxicity and achieve steady state therapeutic levels of drugs over 
an extended period of time. The small size of nanoparticles offers advantages like 
increased cellular uptake and accessibility to locations that are not available to larger 
particles [2]. Flexible surface chemistry of nanoparticles allows possible conjugation of 
ligands and targeting molecule forming potentially effective new chemical entities that 
ultimately improves drug solubility, circulation time, stability and biodistribution of 
particles in the body. The surface properties and size of nanoparticles plays an important 
role in the blood opsonization process and clearance kinetics. The small size of 
nanoparticles allows penetration of cell membrane, binding and stabilization of proteins 
and lysosomal escape after endocytosis [3]. Opsonization of hydrophobic particles occurs 
more quickly than that of hydrophilic particles. Increasing the hydrophilicity by 
modifying the nanoparticle surface with chains of hydrophilic and flexible polymers 
reduces surface adsorption of blood serum proteins and shield nanoparticles from 
opsonins reducing clearance by monocytes and macrophages. The ability to functionalize 
the nanoparticles with targeting moieties, imaging agents, and drug payloads enables the 
synthesis of multimodal complexes that may provide patients with improved treatment 
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specificity and highly sensitive imaging capabilities to monitor treatment progress and 
outcomes [4]. Conjugating targeting molecules to the surface of nanoparticles enables 
manipulation of biodistribution by exploiting difference in molecular interactions 
between normal and malignant cells [5]. Nanoparticle targeting can be done with active 
and passive mechanisms. Passive targeting mechanism, known as enhance permeability 
and retention (EPR), takes advantages of the leaky vasculature and poor lymphatic 
drainage of cancer tissues. Active targeting mechanism has targeting molecules 
conjugated to the surface of nanoparticles and takes advantage of molecular recognition 
interactions such as ligand-receptor and antibody-antigen [6, 7]. However, defining 
highly specific and nonimmunogenic targeting agents that are able to transport 
nanocarriers to target tissues still remains as one of the challenges in nanomedicine.   
 
Table 7: Nanoparticle systems for drug delivery applications 
 
Types of 
nanoparticles 
Advantages Disadvantages Applications 
Inorganic 
Nanoparticles 
Eg silica based, 
cadmium 
based, metal 
based, ceramic 
based 
• Inert and  
biocompatible 
• Easy surface 
modification 
• Stable over broad 
range of temperature 
and pH 
• Slow biodegradation 
• Repeated  
administration causes 
toxicity 
• MR contrast 
agents 
• In vivo cancer 
detection 
• Thermal therapy 
• Targeted delivery 
Polymeric 
Nanoparticles 
Eg PLA, PLGA 
• FDA approved 
• Biodegradable 
• Easy surface 
modification 
• Entrapment of polar 
and non polar drugs 
• Polymer toxicity 
• Low entrapment load 
• Rapid release 
• Immunogenicity 
• Targeted drug 
delivery 
• In vivo cancer 
diagnosis 
Microbubbles • FDA approved 
• Controlled release 
• Targeted delivery 
• Ease of synthesis 
and modification 
• Short blood half life 
• Gas core exhaled 
through lungs 
• Targeted drug 
delivery 
• Contrast agents 
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Dendrimers • Easy surface 
modification 
• Precise size control  
• High drug carriage 
due to branched 
structure  
• In vitro toxicity 
• Compatibility issues 
may cause hemolysis 
• Targeted drug and 
gene delivery  
Micelles • FDA approved 
• Entrapment of both 
polar and non polar 
drugs 
• Thermodynamically 
stable 
 
•Low hydrophobic 
core 
• Limited drug loading 
• Drug precipitation in 
physiological fluid 
• Targeted drug 
delivery 
Liposomes • FDA approved 
• Biodegradable, non 
toxic, non antigenic 
• Surface amenable 
for modification 
• Low systemic 
toxicity 
• Prolonged half life  
• Entrapment of both 
hydrophilic and  
hydrophobic drugs 
• Controlled drug 
release 
• Short shelf half life 
• Inflammation 
• Gene delivery 
• Controlled drug 
delivery 
• Targeted drug 
delivery 
 
4.3 Liposomes in Drug Delivery 
Liposomes are spherical self closed structures composed of phospholipids that form 
multilamellar, concentric bilayer vesicles, with lipid layers separated by layers of 
aqueous media [1, 8-10]. The chemical composition, structure and colloidal size of 
liposome can be controlled by preparation methods that will be useful in various 
applications. Controlling the reaction conditions, liposomes can be manufactured with a 
different diameter ranging from several nanometers to micrometers. They benefit from 
spherical membrane, surface characteristics which may be charged or uncharged based on 
the selection of phospholipids. Amphiphilic characteristics of liposomes allow them to 
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solubilize a wide range of compounds. Owing to its amphiphilic characters, liposomes 
offer several advantages as a drug delivery vehicle. Liposomes can be used to load both 
hydrophobic and hydrophilic drugs. Therefore, liposomal drug delivery system is widely 
used in delivering anti-cancer agents. Liposome are the first therapeutic nanomedicine to 
reach commercialization with the FDA approval of Doxil in 1995 [11]. The success of 
liposomes as a drug delivery vehicle can be attributed by its successful translation to 
clinic (Table 8).  
Table 8: Currently used liposomal drugs in clinic 
 
Product Drug Indications 
Doxil/Caelyx  
   
Doxorubicin Kaposi’s sarcoma 
 
Myocet    
 
Doxorubicin  Metastatic breast cancer 
Daunoxome Daunorubicin Kaposi’s sarcoma, breast 
and Lung cancer 
 
Amphotec    
 
Amphotericin-B Fungal infections, 
Leishmaniasis 
Fungizone   Amphotericin-B Fungal infections, 
Leishmaniasis 
AmBisome     
 
Amphotericin-B Fungal infections 
Abelcet    Amphotericin-B Fungal infections 
VENTUS    
 
Prostaglandin-E1   Systemic inflammatory 
diseases 
ALEC    
 
Dry protein-free powder of 
DPPC-PG 
 
Expanding lung diseases in 
babies 
 
Topex-Br     
 
Terbutaline sulfate Asthma 
Depocyt   
   
Cytarabine Cancer Therapy 
Novasome    
 
Smallpox vaccine Smallpox 
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Mikasome    Amikacin Bacterial infection 
VincaXome     
 
Vincristine Solid Tumors 
Autragen    
 
Tretinoin Kaposi’s sarcoma 
 
Liposomes have been, and continue to be the most intensively researched drug delivery 
systems over few decades. However, conventional liposomes are cleared rapidly from the 
circulation by the macrophages which are located mainly in the liver, spleen and bone 
marrow [8, 12, 13]. The use of modified flexible hydrophilic polymers such as 
polyethylene glycol (PEG) which provides a protective hydrophilic layer at the surface of 
the liposome reduced the clearance of liposome from reticuloendothelial system (RES) [9, 
14, 15].  Such PEGylated liposome, also known as Stealth liposome, have prolonged 
circulation time [10, 16], an improved pharmacokinetic profile compared with that of a 
free drug [17].  
Tumor cells grow indefinitely by forming new vessels to provide nutrients for growth by 
a process called angiogenesis. During the formation of these new vessels, solid tumors 
have the presence of intercellular gaps in the endothelium. One of the major 
characteristics of solid tumors is the lack of effective lymphatic drainage. The 
intracellular gaps along with this lack of lymphatic drainage provide a leeway for the 
extravasation of molecules with a large particle size into tumor cells. This passive 
accumulation phenomenon in solid tumors is known as enhanced permeability and 
retention effect (EPR). The EPR effect is considered a heterogeneous process because of 
the high variability between different types of tumors, from patient to patient, and within 
the tumor itself where there is a vast difference in vascular permeability [18-20]. 
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Therefore, the EPR effect associated with liposome results in different pharmacokinetics 
of the liposomal formulation of drugs compared to the naked drug. The ability to modify 
the surface of the liposome enables selective targeting of the liposome and liposomal 
anticancer drugs via specific ligands against antigens expressed on malignant cells. 
Targeting strategies are exploited to optimize the drug bioavailability to obtain higher 
accumulation of liposome accumulation. However, it should be noted that improved 
therapeutic efficacy is not necessarily a consequence of increased liposomal delivery to 
the target but seem to be model dependent [21]. Several studies have described the 
potential methods of active targeting the liposome with specific antibodies (HER-2), 
targeting peptide (RGD), and ligands targeting proteins expressed on cancer cell 
membrane (folate). Although some studies showed a marginal improvement in survival 
with ligand targeted liposome, for many targets, ligand mediated targeting of liposomes 
will result in little or no therapeutic improvement over passive targeting [22]. Various 
strategies have emerged with liposomal drug delivery to obtain elevated tumor to normal 
drug ratios. Externally triggered light and thermo sensitive liposome, receptor targeted 
pH and endogenous enzymatically triggered liposomes are some of the advanced and 
prospective strategies explored on liposomal drug delivery.  
Acid triggered release of the liposomal content has been one of the most widely 
investigated release mechanism of liposome. pH sensitive liposomes, after internalization 
witnesses the change in the acidic environment where the enzymatic activity releases the 
content of liposomes. Another approach of acid triggered liposomes is the use of 
fusogenic lipid to synthesize liposomes. Lipoplatin, currently in phase III clinical trial, is 
an example of fusogenic liposome that fuses with the lipid layer of the cell membrane, 
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internalizes and releases cisplatin on the cytoplasm. Light triggered mechanism of release 
is based upon the isomerization, fragmentation of polymerization of lipids upon 
photoexcitation. PEG- liposome formulation containing  bis-SorbPC, a photosensitive 
lipid can polymerize and causes leakage in the lipid bilayer upon UV-excitation [23]. 
Plasmogen photooxidiation as a triggered release strategy proposed by Thompson and co-
workers [24] relies on an increase in membrane permeability upon photooxidative 
cleavage of plasmenylcholine to single chain surfactants. Hyperthermia or heat triggered 
release has significant advantage over other triggering concepts in that liposome tumor 
accumulation was increased due to the increased blood flow and vascular permeability 
[21]. Several liposomal formulations using DPPC/DSPC lipids have been designed and 
studied in vitro to determine the rate of release when heated at 42ºC for 30 min [25, 26].  
Hyperthermia as a triggered release is limited to tumor site that is accessible to local 
hyperthermia. Enzymatic release via the upregulated enzymes in tumor tissue is another 
triggered release mechanism. This mechanism utilizes the cell associated proteases for 
the enzymatic drug release from liposomes [27].  
Liposomal formulations of drug offer the advantage of increasing the efficacy of 
chemotherapeutic drugs while reducing the toxic side effects. This strategy of liposomal 
formulation of drugs has been used for various platinum drugs. SPI-077 is a PEGylated 
liposomal formulation of cisplatin which is composed of HSPC, CH and PEG-derivatized 
phosphatidylethanolamine (PEG-PE). Although SPI-077 exhibited longer circulation half 
life, higher anti-tumor efficacy and a decrease in toxicity compared to free drug, SPI-077 
revealed only modest anti-tumor efficacy in phase I and II studies [28].  
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Lipoplatin, PEGylated liposomal formulation of Cisplatin, is composed of anionic 
phospholipid dipalmitoyl phophatidyglycerol (DPPG), HSPC, CH and PEG-derivatized 
phosphatidylethanolamine (PEG-PE) as depicted in Fig. 16. Lipoplatin, nanoparticle with 
110 nm diameter, has the ability to target tumors and metastasis via EPR effect after 
intravenous administration. Lipoplatin has shown increased concentration in tumors and 
metastases at levels up to 200 fold higher compared to the adjacent normal tissue [29].  
 
Figure 16: Depiction of a lipoplatin nanoparticle, a liposomal formulation of cisplatin. Cisplatin is 
represented as blue sphere surrounded by the lipid bilayer with PEGylated lipid sticking out hair 
like structures (adapted and modified from reference
29
)  
  
The increased accumulation of Lipoplatin is attributed to the anionic lipid DPPG which 
has the ability to survive the lysosome, endosome or cytoplasmic enzyme and to cross the 
cell membrane allowing the encapsulated cisplatin to enter the nuclei [18]. During Phase 
I and II trials, Lipoplatin has shown anti-tumor efficacy similar to that of a free drug in 
advanced squamous cell carcinoma of the head and neck with reduced renal and 
hematological toxicity. Therefore, Lipoplatin has progressed into Phase III clinical trial. 
Lipoxal, a liposomal formulation of oxaliplatin was developed using similar technology 
as Lipoplatin and is composed of HSPC, CH, DPPG, PEG-PE. The mechanism of cell 
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uptake and internalization is similar to Lipoplatin since both formulations use the same 
lipid components. Preclinical studies carried out on tumor bearing mice proved Lipoxal 
to be less toxic to normal tissues without losing its efficacy. However, in Phase I clinical 
trial, mild myelotoxicity, nausea and few cases of peripheral neuropathy were observed at 
doses of 300-350 mg/m
2 
[30]. No serious side effects were observed below 300 mg/m
2
. 
Further studies should be done to demonstrate the antitumor efficacy of Lipoxal. 
Various other targeted liposomal formulations of platinum derivatives are reported in 
literature. Suzuki et al reported transferrin conjugated oxaliplatin encapsulated PEgylated 
liposome and its superior antitumor efficacy than non-targeted and free oxaliplatin in in 
vivo model [31]. Folate receptor targeted liposomal formulation of carboplatin reported 
by Chaudhury et al showed improved therapeutic efficacy in ovarian tumor xenograft 
model compared to free drug or non- targeted liposomes [32]. There are currently no 
targeted liposomal platinum derivatives approved for clinical use. Studies involving the 
targeted liposomes should be further investigated before clinical translation. 
This project introduces liposomes as a drug delivery vehicle for a newly synthesized 
radiolabeled platinum drug, [
18
F]-FCP. The liposome surface is radiolabeled with 
111
In to 
enable distinct SPECT imaging in contrast to PET imaging from [
18
F]-FCP. This enables 
real time visualization of the radiolabeled drug and nanoparticle using bi-modal non 
invasive imaging. Further details on the synthesis and evaluation of [
18
F]-FCP and the 
liposomal formulation are discussed in Chapter 5 and 6 respectively. 
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CHAPTER 5: FLUORINATED CARBOPLATIN    
DERIVATIVE: A NOVEL THERANOSTIC ANTICANCER 
DRUG FOR THERAPY AND IMAGING 
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5.1 Introduction 
This chapter deals with the development and evaluation of fluorinated carboplatin 
derivatives. This chapter presents the development of cold reference compound, F-19 
labeled carboplatin, cisdiammine {2-(5-fluoropentyl)-2-methylmalonato- κ2,O, O’} 
platinum(II) (
19
F-FCP), and its in vitro cytotoxicity evaluation in comparison with 
cisplatin and carboplatin. Further, this chapter also presents the development of F-18 
labeled carboplatin derivative ([
18
F]-FCP) and its in vivo evaluation in normal and 
xenograft model. 
Platinum based anti-cancer drugs play a pivotal role in the treatment of various solid 
tumors in clinic today. Since the accidental discovery of its biological properties by 
Rosenberg et al [1]  many years ago, Cisplatin has made a major impact in the therapeutic 
treatment of testicular and ovarian cancers, and along with carboplatin, is still widely 
used today for the treatment of ovarian, cervical, head & neck and lung cancers including 
advanced non-small cell lung cancer (NSCLC). Like other cytotoxic agents, however, 
adequate dosage administration of platinum chemotherapy is still hampered by the toxic 
effects of the drug on normal tissues and functions. Both tumor regression and normal 
organ toxicity are directly related to amount of drug that reaches the tissues. Reduced 
retention of drug in the tumor is further compromised by drug efflux due to multi-drug 
resistance (MDR) and limited drug penetration. Currently, there is no direct means by 
which the amount of platinum drug in the tumor and normal tissues can be determined in 
individual patients, a major obstacle in knowing which patient tumors have how much 
drug and hence which patients are more likely to respond to treatment. Despite the 
multifactorial nature of platinum resistance, reduced intracellular drug accumulation is 
one of the most consistently identified features of Cisplatin-resistant cell lines [2-4], 
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including resistant NSCLC cell lines [5-10]. More recently, a recent clinical study 
established a relationship between tissue platinum concentration and response in NSCLC, 
which suggests that reduced platinum accumulation might be an important mechanism of 
platinum resistance in the clinical setting [11]. The use of radio labeled drug candidates 
and PET/SPECT imaging, in early drug development, provides unique information that 
bridges the gap between molecular biology, pharmacology, pathology and the design of 
new generation therapeutic strategies and drug systems. For example, by labeling a 
chemotherapeutic ([
18
F)-Paclitaxel) agent with a positron emitting radionuclide and by 
monitoring the kinetics of the radioactivity in the tumor, in vivo chemoresistance have 
been studied [12, 13]. Two approaches of radiolabeling platinum drugs; one using Pt 
isotopes to synthesize drug and the other using 
13
N to label cisplatin have been published. 
Baer et al [14] described the microscale synthesis of various platinum compounds labeled 
with 
191
Pt. Leal et al [15] established the production of radioactive cisplatin with and 
without a cadmium capsule by irradiating cisplatin with thermal and epithermal neutrons 
flux. This approach irradiates an intact drug to convert stable Pt to radioactive Pt. 
However, this approach could produce radiation induced damage to the chemical 
structure of the compound. Speigeleer et al [16] developed a microscale synthesis of 
labeling cisplatin with cyclotron produced [
13
N]. Areberg et al [17] synthesized cisplatin 
using 
191
Pt, 
193m
Pt, and 
195m
Pt and calculated the absorbed doses to various organs and 
tissues as well as effective doses from the radionuclides after administration to humans.  
Thus, significant research efforts so far, to improve the overall efficacy of platinum-based 
therapy in solid tumors, have all emphasized the need to know the most important factors 
related to response: accumulation and retention of drug in tumors in a heterogeneous 
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tumor, which is affected by a unique microenvironment such as tumor hypoxia.  In light 
of this, this research project aims to better utilize and update on the present therapeutic 
norm of platinum-based anticancer therapy and this has led us to develop and evaluate a 
[
18
F]-FCP, by introducing a molecular imaging entity [
18
F]-labeled malonic acid 
coordinated to the drug which enables, through non-invasive PET imaging, quantitative 
measurement of drug concentration in multiple tumors and normal tissues within an 
individual patient. The rest of this chapter details the approach and methodologies 
developed for the radiosynthesis of 
19
F-FCP and [
18
F]-FCP including in vitro, ex vivo and 
in vivo imaging studies.  
5.2 Experimental Section 
5.2.1 Materials 
All reagents and solvents were purchased from Sigma-Aldrich and used without further 
purification unless otherwise indicated. All cold reactions were performed under argon 
atmosphere in oven-dried glassware. Flash chromatography was performed employing 
Sigma-Aldrich 230-400 mesh60 Å silica gel. TLC (Sigma-Aldrich, Saint Louis, MO) was 
performed using silica gel-coated aluminum plates with F-254 indicator (250 mm, 20 
cm20 cm, Whatman). NMR (Piscataway, NJ) spectra (1H-NMR, 13C-NMR, and 
19
F-
NMR, 
195
Pt-NMR) were obtained using Varian Mercury 300 MHz and Varian Inova 400 
MHz (Sigma-Aldrich, Saint Louis, MO) using tetramethylsilane as an internal standard. 
Aqueous [
18
F]-fluoride was produced by the 
18
O (p,n)
18
F reaction, in a PET tracer 
cyclotron (GEMedical Systems, Wausheka, WI, USA), by the irradiation of an 
isotopically enriched 98% [
18
O] water (Rotem Industries, Ber Sheva, Israel) target. For 
fluoride trapping, Sep-Pak Light quaternary methyl ammonium (QMA) cartridge was 
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used in manual synthesis from Waters Corp. (Milford, MA, USA). Radio-HPLC analysis 
was carried using a Waters HPLC pump (Waters, Model 1525) equipped with UV 
detector (Waters, Model 2489) and radiation detector (Bio-scan, Model B-FC-3300) 
connected in series. For reverse phase HPLC, a Waters® Nova-Pak 4µ C18 150 x 3.9 
mm column was eluted isocratically with 25/75 ACN/Water containing 0.1%TFA at flow 
rate of 1 mL/min. Radio-TLC was performed on a radio-TLC scanner (BioScan, Model 
AR/2000). Radioactivity was measured with dose calibrator Captintec CRC-15 PET. 
Gamma counting was measured by gamma counter (Gamma counter (LKB Wallac 1282 
compugamma CS universal gamma counter/Perkin Elmer). Animals, normal adult 
athymic female nude mice, were purchased from Harlan laboratories, USA. 
 
5.2.2 Synthesis of Cold Reference (19F-FCP) 
 
5.2.2.1 Diethyl 2-(5-bromopentyl)-2-methylmalonate (1)  
A solution of diethyl methylmalonate (6.0 g, 34.5 mmol) in dry dimethylformamide (50 
mL) was treated portion wise with sodium hydride (1.5 g of a 60% dispersion, w/w, in 
mineral oil, 38 mmol) with cooling. The reaction mixture was stirred for 30 min at 
ambient temperature and treated with 1,5-dibrompentane (11.9 g, 51.8 mmol). The 
reaction mixture was heated at 50 °C overnight and quenched by adding 30% ammonium 
hydroxide solution. Distilled  water (50 mL) was added in to the reaction mixture and 
extracted with  dichloromethane (3 x 50 mL). The organic layer was washed with brine, 
dried over anhydrous sodium sulfate and concentrated under reduced pressure. The 
residue was purified by flash chromatography using 5% ethyl acetate in hexane to give 
alkyl malonate 1 as colorless viscous oil (8.0 g, 72%) (Scheme 1.): 
1
H-NMR (300 MHz) 
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(CDCl3)  1.20 -1.33 (m, 2H), 1.25 (t, J = 7.32 Hz, 6H), 1.40 (s, 3H), 1.42 — 1.51(m, 
2H), 1.81 — 191 (m, 4H), 3.39 (t, J = 6.73 Hz, 2H), 4.17 (q, J = 7.32 Hz, 4H); 13C-NMR 
(75 MHz) (CDCl3)  13.9, 19.7, 23.3, 28.2, 32.3, 33.4, 35.1,53.4, 60.9, 172.1; ESI-MS 
[M+Na]
+
m/z calcd for C13H23BrO4+Na  345.07 found 345.08.(NMR Fig 1) 
 
5.2.2.2 Diethyl 2-methyl-2-(5-(tosyloxy)pentyl)malonate (2)   
 
To a solution of alkyl malonate 1 (3.2 g 10 mmol) in dry acetonitrile (30 mL), silver 
tosylate (3.48 g, 12.5 mmol) was added. After the reaction mixture was refluxed for 24 h 
under an argon atmosphere, the reaction mixture was filtered through celite to remove the 
silver salt and solvent was evaporated under reduced pressure. The residue obtained from 
the solvent evaporation was purified by flash chromatography using 10% ethyl acetate in 
hexane to give tosylate precursor 2 as a colorless viscous oil (3.9 g, 96%): 
1
H-NMR (300 
MHz) (CDCl3)  1.18 — 1.25 (m, 2H), 1.23 (t, J = 7.22 Hz, 6H), 1.26 — 1.35 (m, 2H), 
1.36 (s, 3H), 1.61 – 1.68 (m, 2H), 1.77 — 1.81 (m, 2H), 2.45 (s, 3H), 4.00 (t, J = 6.44 Hz, 
2H), 4.16 (q, J = 7.22 Hz, 4H), 7.35 (d, J = 8.19 Hz, 2H) 7.78 (d, J = 8.19 Hz, 2H); 
13
C-
NMR (75 MHz) (CDCl3)  13.7, 19.4, 21.1, 23.2, 25.2, 28.1, 34.8, 53.1, 60.7, 70.1, 127.4, 
129.6, 132.8, 144.4, 171.7; ESI-MS [M+Na]
+
m/z calcd for C13H23BrO4+Na  437.16 
found 437.43.(NMR Fig 2) 
 
5.2.2.3 Diethyl 2-(5-fluoropentyl)-2-methylmalonate (3)  
To a solution of tosylate 2 (2.1 g, 5 mmol) in dry THF (20 mL), a solution 
tetrabutylammonium fluoride TBAF (1 M solution in THF, 1.58 g, 6 mL, 6 mmol) was 
added dropwise under argon atmosphere. The reaction mixture was stirred at 60 °C for 3 
h. The reaction mixture was cooled to room temperature and solvent was evaporated 
under reduced pressure. The product obtained from the solvent evaporation was purified 
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by flash chromatography using 10% ethyl acetate in hexane to give fluoropentyl malonate 
3 as a light yellow colored viscous oil (1.1 g, 84%): 
1
H-NMR (300 MHz) (CDCl3)  1.24 
(t, J = 7.32 Hz, 6H), 1.25 -1.34 (m, 2H), 1.40 (s, 3H), 1.36 — 1.48 (m, 2H), 1.61 — 1.78 
(m, 2H), 1.83 — 1.89 (m, 2H), 4.17 (q, J = 7.32 Hz, 4H), 4.34 (t, J = 6.15 Hz, 1H), 4.50 (t, 
J = 6.15 Hz, 1H); 
13
C-NMR (75 MHz) (CDCl3)  13.87, 19.66, 23.79, 25.33, 25.40, 29.89, 
30.15, 35.25, 53.43, 60.92, 82.49, 84.68, 172.12; ESI-MS [M+Na]
+
m/z calcd for 
C13H23FO4+Na  285.15  was found 285.31. (NMR Fig 3, 4) 
 
5.2.2.4 2-(5-Fluoropentyl)-2-methylmalonic acid (4)   
To a stirred solution of fluoropentyl malonate 3 (310 mg, 1.5 mmol) in THF:MeOH:H2O 
(6:3:1, 15 mL) was added lithium hydroxide monohydrate (631 mg, 15 mmol). The 
reaction mixture was stirred 24 hr at room temperature. After the reaction was complete, 
the organic solvents were removed under reduced pressure. The aqueous layer was 
acidified with oxalic acid solution (1 mol) to pH 2-3 and then extracted with diethyl ether 
(3 x 25 mL). The combined organic layers were dried over anhydrous sodium sulfate and 
then concentrated under reduced pressure. The residue was dissolved in chloroform, 
undissolved residue was filtered and the filtrate was concentrated under reduced pressure 
to give reference compound ([
19
F]-FPMA) 4 (208 mg, 86%) as a white solid: mp = 102-
104 °C: 
1
H-NMR (300 MHz) (CDCl3)  1.32-1.47 (m, 4H), 1.49 (s, 3H), 1.65-1.78 (m, 
2H), 1.90-1.94 (m, 2H), 4.37 (t, J = 6.05 Hz, 1H), 4.49 (t, J = 6.05 Hz, 1H) 10.48 (s, 2H); 
13
C-NMR (75 MHz) (CDCl3)  20.09, 24.22, 25.59, 25.66, 30.14, 30.40, 35.63, 54.03, 
83.04, 85.22, 178.43; 
19
F-NMR (300 MHz) (CDCl3) (coupled)  -218.88 (m); ESI-MS 
[M+Na]
+
m/z calcd for C9H15FO4+Na  229.09 found 229.09. 
1
H-NMR, spectra is shown 
in NMR Fig 5,6. 
- 78 - 
 
5.2.2.5 Non-radioactive Reference Compound 19F-FCP  
Cisplatin 50 mg and silver nitrate 50 mg was dissolved in nanopure water (2.5 mL) and 
reaction was stirred at room temperature for overnight in protected light. After filtration 
of the precipitated silver chloride, one equivalent 2-(5-Fluoropentyl)-2-methylmalonic 
acid (4) was added, and the mixture was stirred at room temperature for 2 days. Product 
was purified by Sep-Pak purification method using water as eluent. Finally, water 
fraction was lyophilized to give fluorinated carboplatin drug. Analysis of Carboplatin 
Derivative 
1
H-NMR (300 MHz) (D
2
O) δ 1.32-1.47 (m, 4H), 1.49 (s, 3H), 1.65-1.78 (m, 
2H), 1.90-1.94 (m, 2H), 4.50 (t, J = 6.05 Hz, 1H), 4.66 (t, J = 6.05 Hz, 1H) ; 
19
F-NMR 
(300 MHz) (D2O) δ -218.88 (m);:195Pt-NMR (300 MHz) (D2O) δ -1596 (broad 
singlet).(NMR Fig 7) 
5.2.3 Manual Synthesis and Characterization of [18F]-FCP 
Radiosynthesis of [
18
F]-FPMA was carried out using the tosylate precursor. [
18
F] Fluoride 
was produced by the 
18
O (p,n)
18
F  reaction in a PETtrace cyclotron by the irradiation of 
an isotopically enriched [
18
O] water target using a 16 MeV proton beam. [
18
F] Fluoride 
was then passed through a QMA Sep-Pak that was preconditioned with (0.25 mol) 
potassium carbonate solution followed by sterile water. The trapped [
18
F] Fluoride was 
eluted with a solution having 0.08 mL of potassium carbonate (0.25 mol) and 0.42 mL of 
sterile water into 10 mL V vial containing a solution of Kryptofix (12 mg) in dry 
acetonitrile (0.8 mL). The reaction mixture was dried with the addition of dry acetonitrile 
at 80 °C. After drying 4 mg tosylate precursor in acetonitrile (0.8 mL) was added and the 
reaction heated at 110 °C for 10 min. The reaction mixture was cooled for 5 min and then 
solvent evaporated under vacuum and helium flow room temperature. Base hydrolysis 
was accomplished by the addition of methanolic NaOH solution in 2 mL of 
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(DCM:MeOH; 9:1) for 20 min at  45 °C. After solvent evaporation sodium citrate buffer 
(pH 3) and 3 mol HCl (1.5:0.5 mL) was added. The reaction mixture was passed through 
a preconditioned C18 column and eluted with 2 mL ethanol. The ethanol was evaporated 
at 45°C under vacuum and helium flow. The final [
18
F]-FPMA was redissolved in water 
and aqua platinum complex was added to the activity vial at 75 °C for 30 min.  In the 
reaction some of the unreacted starting compound, [
18
F]-FPMA was observed by HPLC 
analysis. Final [
18
F]-carboplatin derivative was purified by QMA Sep-Pak ion-exchange 
cartridge.   
5.2.4 Automated Synthesis and Characterization of [18F]-FCP  
Encouraged by the feasibility of manual synthesis of [
18
F]-FCP, we initiated the 
development of automated synthesis of [
18
F]-FCP. Automation provides benefits of 
reduced duration of synthesis, reduced waste, reproducibility and scaled up reaction 
without personnel exposure. 
Automated radiosynthesis of [
18
F]-FCP was carried out on Allinone Synthesizer (Trasis, 
Belgium) (Fig. 17) via [
18
F]-FPMA route as shown in the Scheme 2. Briefly, initial 
optimization of automated radiosynthesis [
18
F]-FPMA and purification was carried out on 
Allinone Synthesizer based on earlier manual radiosynthesis. Radiochemical yield (RCY) 
and radiochemical purity (RCP) was confirmed by radio-HPLC. The radiosynthesis 
procedure for [
18
F]-FCP was a three step reaction process. Each step was programmed as 
a sequence with appropriate macros in the automated synthesizer. Each sequence was 
optimized along the reaction progression to produce a final product, [
18
F]-FCP, with high 
radiochemical yield.  
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Briefly, the manual synthetic procedure involves the synthesis of platinum aqua complex 
ahead of the reaction. The pre-made platinum aqua complex was placed in Allinone 
Synthesizer in a closed vial under nitrogen protection. After purification and evaporation 
of ethanol solvent from [
18
F]-FPMA, it was incubated with platinum aqua complex at 
82°C for 30 mins to yield [
18
F]-FCP. Final [
18
F]-FCP was characterized and 
radiochemical purity (RCP) was confirmed by radio-HPLC.  
 
Figure 17: Automated synthesis of [
18
F]-FCP using AllInone Synthesizer. The cassette for the three 
step reaction was prepared using manifolds. Machine test was performed to verify the optimal 
vacuum, pressure and the movement of all components before placing the manifold in the synthesizer 
as shown above. After the placement of the cassette, the cassette test was performed to test the leak, 
vacuum in the reactor vials and the syringe positions. After all the tests were successful, reagent vials 
were placed as shown above and the pre programmed sequences for the synthesis was started for the 
complete synthesis procedure. 
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5.2.5 Cell Lines and Culture Conditions 
All cell lines were maintained in humidified incubator at 37 °C and 5% CO2. Human 
Cervical Adenocarcinoma (KB 3-1 and KB 8-5) were purchased from National Institute 
of Health (NIH). Lung Carcinoma (A549), Ovarian Carcinoma (SK-OV-3), Colorectal 
Carcinoma (COLO-205), Renal Carcinoma (A498) and Prostate Carcinoma (LNCap) was 
purchased from ATCC. Head and Neck Carcinoma (FaDu) cell line was a gift from Dr. 
Andrei Pugachev at Virginia Commonwealth Massey Cancer Center. Briefly, KB-3-1 and 
KB 8-5 cells were grown in DMEM/High glucose medium supplemented with 10% fetal 
bovine serum (FBS), 5mM L-Glutamine, Penicillin (100U/ml), Streptomycin (100µg/ml) 
and Amphotericin B (0.25 ug/ml). KB-8-5 cell lines were grown in similar media 
supplemented further with 10ng/ml colchicine. COLO-205, FaDu, A498, LNCap cells 
were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS 
Penicillin G (100U/ml), Streptomycin (100µg/ml) and Amphotericin B (0.25 ug/ml). The 
cells were grown to 70-80% confluency before using for the experiments. 
5.2.6 Tumor Xenograft/Animal Model 
KB-3-1 and KB 8-5 cells were maintained in DMEM/High glucose medium 
supplemented with 10% fetal bovine serum (FBS), 5mM L-Glutamine, Penicillin 
(100U/ml), Streptomycin (100µg/ml) and Amphotericin B (0.25 ug/ml). 
Female athymic nude mice, (4-6 weeks old, weight: 18-25 g) were purchased from 
Harlan laboratories, USA and provided with food and water ad libitum. Animal 
experiments were approved and performed according to the policies and guidelines of the 
Animal Care and Use Committee (IACUC) at Virginia Commonwealth University. KB-
3-1 and KB-8-5 cells were cultured as mentioned above and collected for implantation. 
Tumor cells 2.5×10
6
/100µL (KB 3-1), 2.5.0×10
6
/100µL (KB 8-5) in media without 
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serum) were injected subcutaneously into the dorsal region on the right shoulder (KB8-5) 
and left (KB 3-1) shoulder of athymic nude mice. Following subcutaneous implantation 
digital caliper measurement of tumor size was accessed, once the bulge caused by the 
tumor growth at the injection site was visible, (approximately 5 days).  The tumor volume 
was calculated using the formula 0.523 × (length × width × thickness) and assessed thrice 
per week. 
5.2.7 In vitro Cytotoxicity of 19F-FCP 
The cytotoxicity of 
19
F-FCP was compared with cisplatin and carboplatin by incubating 
in various cell lines. The cell viability of COLO-205, SK-OV-3, FaDu, A549, A498, 
LNCaP, RWPE-1 and KB-3-1 cells treated with cis-platinum and carboplatin, and 
fluorinated carboplatin was evaluated using Cell Titer Glo assay kit (Promega, USA). 
Briefly, depending on the cell type, 3,000 to 4000 cells in 25 µl complete media were 
plated in opaque 384-well plate in triplicates for each cell type and cultured overnight in 
the incubator. The next day the cells were treated with 25 µl drug for final concentrations 
from 0.001 (µM) to 100 (µM) for 72 hrs and 96 hrs. At the end of incubation period 50 µl 
assay reagent was added to each well, and the cell viability was assessed by measuring 
the luminescence, detected by a plate reader (Beckman Coulter). The luminescence 
detected in untreated cells was used as control (100% Viability) to calculate percent 
viability in each treatment groups. Statistical analysis was done using Student’s t-test and 
the p value calculated based on two-tailed test using Microsoft Excel software. P<0.05 
was considered statistically significant. 
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5.2.8 Biodistribution and in vivo Stability Analysis 
Animal experiments were approved and performed according to the policies and 
guidelines of the Animal Care and Use Committee at Virginia Commonwealth University. 
The biodistribution of [
18
F]-FCP was measured in normal adult female nude mice 
(Harlan). Under 2% isoflurane, three group of three mice received an intravenous 
injection (tail vein) of [
18
F]-FCP (1.5-2MBq, in 200µL PBS, at the start of the 
experiment). Under anesthesia, mice were sacrificed by cervical dislocation at 5, 30, and 
90 mins post injection. Whole blood was collected by cardiac puncture, other major 
organs were harvested and weighed, and the radioactivity in the organs/tissues was 
counted in a gamma counter (Gamma counter (LKB Wallac 1282 compugamma CS 
universal gamma counter/Perkin Elmer). The blood activity was used to calculate the 
blood half life. Decay-corrected radiotracer uptake in each tissue at various time points 
was then calculated as the percent injected dose per gram of tissue (%ID/g). 
In vivo stability of [
18
F]-FCP in plasma and urine was determined following radiotracer 
administration in normal female nude mice under 2% isoflurane anesthesia. Samples 
were collected at 5, 30, 60, and 90 minutes following intravenous injection of [
18
F]-FCP. 
The collected samples of plasma were centrifuged for 10 mins at 10,000g. Supernatant 
from these samples was filtered through 0.2µ filter and 200µL plasma supernatant was 
injected into reversed-phase HPLC (column Waters Nova-Pak 4 µ C18 150× 3.9 mm, 
CH3CN/H2O 25:75, containing 0.1% TFA at flow rate 1mL/min). Urine samples were 
also filtered and analyzed in the same HPLC system. 
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5.2.9 PET Imaging Studies 
Small animal PET/CT imaging studies were performed using a Siemens Inveon® 
Multimodality PET/CT system (Siemens Medical Solutions Inc., Knoxville, TN, USA). Ten 
minutes prior to imaging, the animals were anesthetized using 2% isoflurane at room 
temperature until stable vital signs were established. Once the animal was sedated, the animal 
was placed onto the imaging bed under mixtures of O2 (1 mL/min) and 2% isoflurane for 
the duration of the imaging. [
18
F]-FCP (5.5-6 MBq/200 µL) was injected intravenously in a 
normal female nude mouse via the tail vein. Immediately following the injection, a 90 minute 
dynamic scan was performed.  
Nude mice were innoculated with human cervical adenocarcinoma (KB) cell lines to 
establish a xenograft model with one P-glycoprotein (P-gp) non expressing (KB 3-1) and one 
Pgp  expressing (KB 8-5) tumor per animal. [
18
F]-FCP formulation (5.5-6 MBq) was 
injected intravenously in xenograft nude mice via tail vein injection. Static summed up image 
data acquired 60 minutes post injection was acquired for 30 mins. The micro CT imaging was 
acquired following the PET imaging at 80kV and 500μA with a focal spot of 58μm. 
PET images were reconstructed using Fourier Re-binning and Ordered Subsets 
Expectation Maximization (OSEM) 3D algorithm with dynamic framing every 60 
seconds. Reconstructed images were fused and analyzed using Inveon® Research 
Workplace (IRW) software. For quantitation, regions of interest were placed in the areas 
expressing the highest radiotracer activity as determined by visual inspection. The 
resulting quantitative data were expressed in Percent Injected Dose per Gram (%ID/g).  
5.2.10 Protein Extraction and Western Blot 
The KB-3-1 and KB-8-5 tumors were excised from the tumor bearing mice, snap frozen 
in liquid nitrogen and stored in -80
0
C until further use. Approximately 80-100 mg of 
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tumor was excised and homogenized in 500 µLof lysis buffer (Pierce RIPA buffer) 
containing protease inhibitor (PI) (Halt protease inhibitor, Pierce) and EDTA (Pierce) in a 
hand held homogenizer on ice. The tumor lysate was collected and stored in -80
0
C. KB-
3-1 and KB-8-5 cells were also collected and lysed in lysis buffer containing PI/DETA. 
The homogenate/cell lysate were spun down at 12,000 rpm for 15 min and the clear 
supernatant was collected for protein assay. The amount of protein in -supernatant was 
estimated using BCA Protein assay kit (Pierce/Thermo scientific). Twenty µg of protein 
was resolved on 7.5% tris-glycine gel. The proteins were transferred onto PVDF 
membrane, at 100V for 1hr. To prevent non-specific binding of the antibody, the PVDF 
membrane was blocked with Odyssey blocking buffer (Cat No; 927-40000, LiCor) for 1 
hr at room temperature (R.T). The blots were the incubated overnight at 4
0
C with primary 
antibodies, anti-P Glycoprotein antibody (F4) Cat No: ab80594 and rabbit β-actin mAb 
(Cell signaling, Cat No 4970) respectively. After washing the blot with PBS/0.1% 
Tween-20, for four times , the blot was incubated with secondary antibodies, IRDye 
680LT Goat anti-mouse IgG and IRDye 800CW Goat anti-rabbit IgG (Li-Cor) 
respectively. The blot was rinsed in wash buffer and the bands for P-gp and β-actin on 
PVDF membrane was detected using Odyssey CLx. The image was analyzed and 
quantified using Image Studio 2.0 software. 
5.3 Results 
5.3.1 Synthesis of 19F-FCP 
Scheme 1 describes the synthesis of the tosylated precursor and reference standard 
compound [
19
F] 2-(5-fluoro-pentyl)-2-methylmalonic acid (4). The reference non-
radioactive compound 5 was synthesized in four steps starting with commercially 
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available diethyl methylmalonate. Diethyl methylmalonate was alkylated with 1,5-
dibromopentane in presence of NaH to give alkylated compound 1 in 72% yield using the 
procedure of Astles et al. Excess 1,5-dibromopentane was used to avoid disubstitution. 
The bromide was displaced using commercially available silver tosylate to give a 
tosylated precursor 2 in 96% yield. The tosylate group was exchanged for the required 
fluoride by a nucleophilic displacement reaction using tetrabutylammonium fluoride 
(TBAF) to give diethyl 2-(5-fluoropentyl)-2-methyl malonate 3 in 84% yield. 
Fluoropentyl diethyl malonate ester 3 was hydrolyzed using lithium hydroxide under 
mild conditions to give 2-(5-fluoro-pentyl)-2-methyl malonic acid as a white solid with 
50% overall yield. Finally, 2-(5-fluoro-pentyl)-2-methyl malonic acid 4 was incubated 
with platinum aqua complex for 2 days to give F-19 Carboplatin derivative 5. All the 
intermediate compounds and final compound were fully characterized by 
1
H-NMR, 
13
C-
NMR, 19F-NMR, and ESI-MS analysis. Fluorination of compound 3 was confirmed by 
19
F-NMR, which showed the expected multiplet pattern and had a chemical shift in the 
expected region (218.88 for terminal (CH2F)). The calculated molecular mass for purified 
2- (5-fluoro-pentyl)-2-methyl malonic acid was in agreement with experimental value. 
Chemical purity was found to be greater than 98% as determined by analytical HPLC. 
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Scheme 1: Synthesis of cold reference compound 19F-FCP and tosylate precursor of 19F-FCP. Reagents 
and conditions: (a) 1,5-dibromopentane, NaH,DMF, 50 ºC, 12 h, 72%; (b) silver tosylate, ACN, reflux, 12 
h, 96%; (c) TBAF, THF,60 ºC, 3 h, 84%; (d) LiOH/H2O THF/MeOH/H2O (6:3:1), rt, 24 h, 86% (e) 
platinum aqua complex, rt, 2 days. 
 
5.3.2 In vitro Cytotoxicity of 19F-FCP 
A key prerequisite for a drug analog is that it must not alter the anti-tumor activity of the 
parent drug. To directly compare the cytotoxicity of 
19
F-FCP with cisplatin and 
carboplatin, in vitro a panel of eight cell lines of different origin; COLO 205, SK-OV-3, 
FaDu, A549, A498, LNCaP, RWPE-1 and KB-3-1,  was treated with 
19
F-FCP with 
cisplatin and carboplatin at concentrations from 0.001 (µM) to 100 (µM) for 72 hrs and 
96 hrs. At the end of the incubation period, the percent viable cells were evaluated by 
measuring amount of ATP released from viable cells using Cell Titer-Glo reagent. The 
percent viability of each cell line at various concentrations of drugs was plotted and used 
to calculate the IC50 for each drug. Table 9 reports IC50 (50% growth inhibition 
concentration) values for each of the eight cell lines. Different cell lines exhibited 
different sensitivities to platinum compounds depending on their origins, morphologies, 
and tumorigenicites. Based on the cell viability data, the IC50 values for the various 
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platinum compounds demonstrated that cisplatin reduced the cell viability to the greater 
extent than carboplatin, and 
19
F-FCP. The cytotoxicity of 
19
F-FCP was slightly higher 
than carboplatin suggesting that 
19
F-FCP is more potent than carboplatin. Cytotoxic effect 
for all three compounds was time dependent. Increasing the incubation time from 72 
hours to 96 hours reduced the IC50 values for all three compounds indicating that the 
cytotoxic activity of all three compounds was elevated with time. 
 
Table 9: IC50 values of cisplatin, carboplatin and 19F-FCP in various cancer cell lines 
 
 
5.3.3 Radiosynthesis of [18F]-FCP 
Scheme 2 represents manual and automated radiosynthesis of [
18
F] 2-(5-fluoropentyl)-2-
methyl malonic acid ([
18
F]-FPMA) in two steps: (i) Kryptofix-mediated direct 
nucleophilic fluorination and (ii) NaOH base hydrolysis (iii) conjugation with platinum-
aqua complex.  
Radiofluorination of 2  was carried out in the presence of Kryptofix and K2CO3 in 
acetonitrile, optimum conditions of 8-mg precursor, 110 ºC, and 20 min. reaction time 
resulted in >90% RCY of non-hydrolyzed compound 6 as confirmed by radio-thin-layer 
chromatography (TLC) analysis. After radiolabeling, the acetonitrile was evaporated with 
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helium flow under vacuum, and the product was subjected to base hydrolysis. Complete 
hydrolysis was achieved by methanolic sodium hydroxide (3 M) in dichloromethane 
(DCM)/methanol (9:1) for 20 min at 45 ºC. The final product was purified by solid phase 
extraction. After evaporation of the solvent, under vacuum and helium flow, the product 
was re-dissolved in water and adjusted to pH 2–3 using 3 M HCl. The reaction mixture 
was passed through a C18 Sep-Pak column, and the column was washed with 10 mL of 
water to remove free fluoride and byproducts of para-toluene sulphonic acid. The 
product was eluted with multiple 0.5 mL ethanol fractions. Greater than 90% of product 
radioactivity was eluted in fractions 3 and 4. The overall decay-corrected (yield of 7, 50 
min after introduction of [
18
F]-fluoride activity) isolated RCY of [
18
F]-FPMA was 60%, 
and the radiochemical purity (RCP) was more than 98% in 50 min total synthesis time. 
RCP was confirmed by radio-HPLC. Co-injections with non-radioactive fluorinated 
compound gave the same retention time as [
18
F]-FPMA = 4 min. Compound 7 was 
completely dried under helium flow under vacuum. Aqua platinum complex was added to 
the reaction vial 7 for further conjugation at 80 ºC for 30 mins to yield the final 
compound. The final product 8 was purified by QMA anion exchange column. The 
product was eluted with multiple 0.5 mL water fractions. The decay corrected (yield of 
final product, 180 mins after the introduction of [
18
F]-fluoride activity isolated RCY of 
[
18
F)-FCP was 14.3±3.8% (n=3), and the radiochemical purity was more than 98% in 180 
mins synthesis time. RCP was confirmed by radio-HPLC (Fig 17). Retention time of 
[
18
F)-FCP was 1.43 mins (Fig. 18). 
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Scheme 2: Synthesis of [18F]-FCP. Reagents and conditions: (a) K18F/K222, K2CO3, ACN, 110 _C, 10 
min condition used for manual synthesis; (b) glass microfluidic device,K18F/K222, K2CO3, ACN, 190 ºC, 
condition used in automated microfluidic synthesis; (c) 3 mol NaOH, DCM/MeOH (9:1), 45ºC, 20 min; (d) 
3 M HCl, in manual and sodium citrate buffer (pH 2.79) in microfluidic synthesis, was used for pH 
adjustment (pH 2–3), (e) platinum aqua complex, 82 ºC, 30 mins. 
 
 
 
 
Figure 18: Sample was run on Waters® 4µ C18 150 x 3.9 mm column; ACN/Water (0.1%TFA) 25/75 
with flow rate of 1mL/min; Fig A. RT = 3.38 min. of Radioactivity [18F]-FPMA; Fig B: HPLC profile 
of Platinum coordination reaction; Fig. C: HPLC profile after purification RT=1.43 min of [
18
F]-FCP. 
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5.3.4 Biodistribution and in vivo Stability Analysis 
Table 10 and Fig.19 show the biodistribution of [
18
F]-FCP in female nude mice. The 
radiotracer demonstrated rapid blood clearance with less than 2% of radioactivity 
remaining in the circulation after 1 h. The blood half life was calculated to be 10-12 mins. 
Most organs showed low accumulation of the radiotracer and radioactivity was 
predominantly cleared through the kidneys with greater than 95% cleared 1 h after 
injection. 
The in vivo stability of [
18
F]-FCP in plasma and urine was assessed during the first 60 
mins after intravenous administration in normal nude mice. The stability of [
18
F]-FCP 
was analyzed by radio-HPLC at 5, 30, 60, and 90 mins post administration. The radio 
HPLC peak of the plasma samples injected appeared at the same retention time as the 
initial injected radiotracer (Fig. 20), demonstrating an intact [
18
F]-FCP 60 min-post 
injection. No radioactivity was detected in 90 min samples which could be attributed to 
the fast physiological clearance of the radiotracer from the blood. The radio HPLC peak 
of the urine samples injected also appeared at the same retention time as the initial 
injected radiotracer demonstrating the intact [
18
F]-FCP (data not shown).  
Table 10: Biodistribution of intravenously injected [
18
F]-FCP in nude mice (n=3 per time point).  
Data are presented as %ID/g (mean±sem) values determined through gamma counting 
Organs       5 Mins        30 Mins       90 Mins 
Blood 4.56±0.67 1.09±0.62 0.99±0.57 
Heart 1.5±0.09 0.62±0.36 0.71±0.41 
Lungs 3.20±0.018 1.27±0.73 1.37±0.79 
Liver 4.54±0.50 3.48±2.01 2.28±1.31 
Spleen 1.43±0.50 0.91±0.53 1.70±0.98 
Stomach 1.36±0.37 0.75±0.43 0.38±0.22 
Intestine 2.84±0.31 2.28±1.31 1.65±0.95 
Kidneys 10.47±2.77 4.98±2.88 4.63±2.67 
Skin 4.40±0.70 1.30±0.75 1.13±0.65 
Muscle 2.56±0.73 0.69±0.40 0.678±0.38 
Brain 0.22±0.01 0.10±0.06 0.12±0.072 
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Figure 19: Biodistribution of [18F]-FCP in normal adult female nude mice (n=3) at 5, 30, 90 mins 
after injection. Radio tracer uptake in % ID/g was determined by gamma counting. 
 
 
 
 
 
Figure 20:  Plasma sample was run on Waters® 4µ C18 150 x 3.9 mm column; ACN/Water 
(0.1%TFA) 25/75 with flow rate of 1mL/min at different time point; Fig. A: 05 min; Fig. B: 30 min; 
Fig. C: 60 min. 
Femur 1.02±0.17 0.78±0.45 0.53±0.30 
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5.3.5 PET Imaging Studies  
 
[
18
F]-FCP imaging in nude mice was performed to establish PET imaging feasibility and 
biodistribution. Dynamic images acquired for 90 mins illustrate the full body distribution 
of [
18
F]-FCP (Fig. 21). [
18
F]-FCP had the highest uptake in kidneys. Accumulation of 
radiotracer was also seen in lungs and liver in early time points. High uptake in the 
kidneys seems to reflect urinary excretion of the tracer which can be attributed to the 
radioactivity present in the urine during the scan. Images showed the subsequent 
clearance of radiotracer with time. Ex-vivo biodistribution data on the tissue distribution 
correlated to the imaging data.  
 
 
Figure 21: A female nude mouse was injected (i.v) with 5.5-6 MBq of [
18
F]-FCP derivative and 
imaged using an Inveon PET/CT scanner (SIEMENS,USA). Dynamic image data acquired between 5, 
30, 60 and 90 minutes post injection was reconstructed (FBP and OSEM/MAP) and analyzed. 
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Static summed up images acquired 90 mins post radiotracer administration illustrate the 
full body distribution of [
18
F]-FCP in tumor bearing mice (Fig. 22). Major uptake was 
observed in liver and abdominal region. Quantification of the 90-min static summed up 
scans of xenograft tumors (KB3-1 and KB 8-5) with ROI analysis showed differential 
uptake of radiotracer in these tumors. Images showed a significant difference in uptake 
between Pgp (+ve) and Pgp (-ve) tumor. 
 
  
 
Figure 22: Nude mice were innoculated with human cervical adenocarcinoma (KB) cell lines to 
establish a xenograft model with one P-glycoprotein (P-gp) non expressing (KB 3-1) and one Pgp  
expressing (KB 8-5) tumor per animal.  [
18
F]-FCP (5.5-6 MBq) was injected intravenously in 
xenograft nude mice via tail vein injection. Imaging was carried out 90 mins post injection using 
Inveon PET/CT (Siemens, USA). Static summed up image acquired 90 mins post injection was 
reconstructed (FBP and OSEM3D/MAP) and analyzed. Image showed that P-gp non expressing (KB 
3-1) tumor has slightly higher uptake of radiotracer than P-gp expressing KB 8-5 tumor. 
  
- 95 - 
 
5.3.6 Protein expression and Western Blotting 
The PET image of the KB-3-1 and KB-8-5 tumor bearing mice showed subtle difference 
in the accumulation of [
18
F]-FCP. To determine whether this differences in the 
accumulation was attributed to level of P-gp, tumors from the imaged mice were taken, 
homogenized and immunoblotted against P-gp. As a loading control β-actin level in the 
tumor were analyzed. The results after normalizing the signal of P-gp to β- actin showed 
that the level of expression of P-gp in KB-8-5 tumor was twice compared with KB-3-1 
tumor.  
5.4 Discussion 
One of the major hindrances in platinum therapy is the assessment between the amount of 
drug administered, the amount of drug that reaches the targeted therapeutic site and 
overall therapeutic efficacy of the treatment. Non-invasive studies of the tissue 
concentrations are rare using radiolabeled platinum. Areberg et al [18] studied the 
antitumor effect of radioactive cisplatin (
191
Pt) on nude mice and demonstrated that 
191
Pt-
cisplatin is a more effective drug than cisplatin in retarding tumor growth on tumor 
growing nude mice. Patient studies by Areberg et al [17, 19] demonstrated the use of 
radiolabeled with 
191
Pt, 
193m
Pt, 
195m
Pt to visualize the uptake of platinum in tumors and 
tissues non-invasively after cisplatin treatment. Dowell et al [20] used 
195m
Pt labeled 
cisplatin and carboplatin to estimate the amount of platinated drug and its metabolites at 
the tumor site and at selected organs using noninvasive imaging. However, the major 
problems with the known platinum radionuclides (
191
Pt, 
193m
Pt, 
195m
Pt, 
197
Pt) is the limited 
supply of the highly enriched platinum isotope needed for the reactor production, and that 
the cross sections needed for the production of platinum radionuclides from cyclotron is 
not very favorable [20].  
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This study demonstrated the feasibility of utilizing our previously published work on 
[
18
F]-FPMA [21] in the synthesis of [
18
F]-FCP. Ease of production and well suited for 
routine use of 
18
F in nuclear medicine application, 
18
F remains the radionuclide of choice 
for PET/CT. In this project, we have presented the results of the radiosynthesis of [
18
F]-
FCP, a theranostic anticancer drug for imaging and therapy, and its feasibility of in vivo 
imaging using PET in animal model. This project addressed a major need to enhance the 
overall efficacy of platinum-based chemotherapy in solid tumors, by introducing F-18 as a 
molecular PET imaging entity as part of the drug to enable the measurement of drug 
concentration in tumors and normal tissues. An important finding of the study was the very 
high stability of the drug in plasma and urine at 60 mins after administration (Fig 20). 
Such stability ensures that the drug is intact in vivo and the radioactivity measured 
throughout the study (in vivo imaging and ex vivo analysis) originates from the intact 
drug instead of the potential metabolites.  
[
18
F]-FCP exhibited uniform pattern of tissue uptake in tissues and tracer clearance 
followed monoexponential blood kinetics. The blood half life is calculated to be 10-12 
mins which is similar to the value presented in the literature for native carboplatin [22]. 
Following intravenous injection of [
18
F]-FCP in normal nude mice, quantification of the 
dynamic images of the 90 mins, the highest activity was recorded in kidneys, bladder and 
urine. Accumulation of [
18
F]-FCP was also recorded in liver and lungs in early time 
points with subsequent clearance with time which is consistent with the findings by 
Ginos et al [23]. Ex-vivo biodistribution data corresponded to the in-vivo findings with 
major accumulation of radiotracer in kidneys and liver. In vitro cytotoxicity assay on 
various cells lines demonstrated that 
19
F-FCP kills cancer cells with greater efficacy than 
carboplatin.  
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5.5 Conclusion 
 
 An automated radiosynthesis of 
18
F-FCP was developed, using our previously developed 
18
F-FPMA radiotracer. In vivo data showed a rapid blood clearance and accelerated renal 
elimination of intact radiotracer. Feasibility of non- invasive imaging and quantitation of 
[
18
F]-FCP was demonstrated in normal and tumor bearing nude mice. 
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NMR Fig 1: 
1
H-NMR and 
13
C-NMR of Diethyl 2-(5-bromopentyl)-2-methylmalonate 
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NMR Fig 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NMR Fig 2:
 1
H-NMR and 
13
C-NMR of Diethyl 2-methyl-2-(5-(tosyloxy)pentyl)malonate 
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NMR Fig 3: 
1
H-NMR and 
13
C-NMR of Diethyl 2-(5-fluoropentyl)-2-methylmalonate 
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NMR Fig4: 
19
F-NMR of Diethyl 2-(5-fluoropentyl)-2-methylmalonate 
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NMR Fig 5: 
1
H-NMR and 
13
C-NMR 2-(5-Fluoropentyl)-2-methylmalonic acid 
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NMR Fig 6: 
19
F-NMR  of 2-(5-Fluoropentyl)-2-methylmalonic acid 
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NMR Fig 7: 1H-NMR, 19F-NMR  and 195Pt-NMR  [F]-FCP 
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CHAPTER 6: LIPOSOMAL CARBOPLATIN: A NOVEL 
DOUBLE RADIOLABELED NANOCONSTRUCT FOR 
DUAL TRACER IMAGING AND THERAPY 
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6.1 Introduction  
  
This chapter deals with the development of liposomal carboplatin formulation. This 
chapter presents the development of [
111
In]-labeled Liposomes and its in vivo evaluation 
in normal nude mice. Further, [
18
F]-FCP encapsulation of [
111
In]-labeled Liposomes to 
develop a dual tracer labeled nanocarrier and its in vivo evaluation in two different tumor 
xenograft bearing nude mice is also presented in this chapter. 
Liposomes are self assembling vesicles composed of lipid bilayers and an enclosed 
fraction of the surrounding aqueous medium [1]. Pharmacokinetics and distribution of 
liposomes can be manipulated by modifying their size, charge, composition and surface 
modification [2, 3]. Amenable surface modification, amphilphilic nature and 
biodegradable properties of liposome make them an appealing vehicle for drug delivery. 
Several attempts of radiolabeling liposomes using various isotopes have been tried for a 
variety of reasons. The major aim of all of these studies using radiolabeled liposomes is 
to follow the fate of liposome in vivo and to measure the distribution of the nanoparticles 
quantitatively ex vivo. Information on the in vivo behavior of liposomes helps in 
optimizing the liposome for novel imaging and therapeutic approaches.  
Varieties of techniques have been developed to label liposomes with radioisotopes. 
Radionuclides such as 
99m
Tc, 
186
Re, 
67
Ga, 
111
In were attached to the liposome using 
chelators or by encapsulating them in aqueous cavity [4]. This project focuses on labeling 
liposomes with 
111
In. Diethylenetriaminepentaacetic acid (DTPA)-derivatized liposomes 
have been widely used to radiolabel with 
111
In [5]. Harrington et al [6] reported detailed 
biodistribution and pharmacokinetics of 
111
In-DTPA-labelled pegylated liposome in nude 
mice bearing a human cancer xenograft. Umeda et al [7] demonstrated the imaging ability 
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of liposomes labeled with 
67
Ga-NTA, and 
111
In-NTA in various mouse tumor models. 
Chow et al [8] compared the therapeutic effect of two different formulations of 
vinorelbine encapsulated 
111
In-Liposomes with varying concentration of polyethylene 
glycol in human colorectal tumor bearing mice. Yang et al [9] evaluated the 
pharmacokinetics of targeted and untargeted 
111
In-doxorubicin liposomes in tumor 
bearing mice in the presence of blood-brain barrier disruption. Mougin-Degraef et al [10] 
designed liposomes with surface radiolabeled with  
111
In- bound to DTPA lipid and the 
aqueous phase labeled with 
125
I-Bolton Hunter-arginine for radioimmunotherapy. Presant 
et al [11] applied Indium-111 labeled phospholipid vesicles to image variety of tumors in 
vivo after intravenous administration in patients. Similarly, Kubo et al [12] determined 
the radiation absorbed dose and tumor detection using Indium-111 labeled liposomes. 
Liposome has wide range of properties that enables its use ranging from drug delivery to 
imaging tumors. 
This project focuses on designing [
111
In] -Labeled Liposome as a drug delivery vehicle 
for [
18
F]-FCP. To our knowledge, there is no study on the synthesis and development of 
carboplatin that combines 
18
F as a molecular imaging entity. Furthermore, there is no 
study that encapsulates [
18
F]-FCP inside [
111
In] -Labeled Liposome. Therefore, this 
project is quite novel in determining the fate of both the drug and the vehicle in vivo 
using non invasive multimodal imaging. This project develops a novel dual tracer labeled 
liposomal nanocarrier as a multimodal imaging/therapy paradigm. 
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6.2 Experimental 
6.2.1 Chemicals 
All chemicals were used as received without further purification. 1,2- dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC),  1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N-diethylenetriaminepentaacetic acid (ammonium salt) (DPPE-DTPA) were purchased 
from Avanti Polar Lipids (Alabaster, AL, USA). 1, 2-distearoyl-sn-glycero-3-
phosphoethanol-amine-N-[methoxy(polyethyleneglycol)-2000] ammonium salt (DSPE-
PEG2000) was bought from Laysan Bio, Inc. (Arab, AL, USA). Cholesterol (Chol), cis-
diamminedichloridoplatinum (II) (Cisplatin), cis-Diammine(1,1-
cyclobutanedicarboxylato)platinum(II) (Carboplatin) were purchased from Sigma-
Aldrich (Steinheim, Germany). Sephadex-G25 and all other materials were purchased 
from VWR. 
Flash chromatography was performed employing Sigma-Aldrich 230-400 mesh60 Å 
silica gel. TLC (Sigma-Aldrich, Saint Louis, MO) was performed using silica gel-coated 
aluminum plates with F-254 indicator (250 mm, 20 cm20 cm, Whatman). NMR 
(Piscataway, NJ) spectra (1H-NMR, 13C-NMR, and 19F-NMR, 195Pt-NMR) were 
obtained using Varian Mercury 300 MHz and Varian Inova 400 MHz (Sigma-Aldrich, 
Saint Louis, MO) using tetramethylsilane as an internal standard. Aqueous [
18
F]-fluoride 
was produced by the 
18
O (p,n)
18
F reaction, in a PET tracer cyclotron (GEMedical 
Systems, Wausheka, WI, USA), by the irradiation of an isotopically enriched [
18
O] water 
(Rotem Industries, Ber Sheva, Israel) target. For fluoride trapping, Sep-Pak Light 
quaternary methyl ammonium (QMA) cartridge was used in manual synthesis from 
Waters Corp. (Milford, MA, USA). Radio-HPLC stability analysis was carried using a 
Waters HPLC pump (Waters, Model 1525) equipped with UV detector (Waters, Model 
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2489) and radiation detector (Bio-scan, Model B-FC-3300) connected in series. For 
reverse phase HPLC, a Waters® Nova-Pak 4µ C18 150 x 3.9 mm column was eluted 
isocratically with 25/75 ACN/Water containing 0.1%TFA at flow rate of 1 mL/min. 
Radio-TLC was performed on a radio-TLC scanner (BioScan, Model AR/2000). 
Radioactivity was measured with dose calibrator Captintec CRC-15 PET. Animals, 
normal adult athymic female nude mice, were purchased from Harlan laboratories, USA. 
111
In-indium chloride in 0.05M HCl (specific activity: 15.70mCi/mL) was purchased 
from Perkin-Elmer (Wellesley, MA) and Triad Isotopes (Richmond, VA). 
6.2.2 [111In]-Labeled Liposome Preparation 
PEGylated liposome was synthesized using the method described my Mougin-degraef et 
al [10]. Briefly DPPC, Chol, DSPE-PEG2000, DPPE-DTPA (60:30:5:5 mole ratio) were 
mixed in a 10 ml vial and dissolved with Chloroform: Methanol (CHCl3:MeOH, 9:1).  
The solvent was evaporated under rotary evaporator to form a lipid film followed by high 
vacuum to remove the residual organic solvent. Dulbecco’s phosphate buffered saline 
(PBS; 1ml) was added and the suspension was sonicated at 50-60ºC for 10 mins. At the 
end of the incubation, the liposome solution was immediately chilled in ice. The resulting 
vesicles were extruded through a series of polycarbonate membrane at 50-60ºC. The 
extruded liposomes were purified using gel chromatography on Sephadex G-25 with PBS 
as an eluent. 
6.2.3 Labeling Procedure 
PEGylated liposome was labeled with 
111
In as previously described by Chow et al.[13]. 
Briefly, 500 µL of preformed liposome was incubated with 20 µL of 
111
InCl3 (Indium 
Chloride in 0.05 M HCl; 3.7–74 MBq) (Perkin Elmer/Triad Isotopes) in 20 µL of 3M 
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sodium acetate buffer (pH 5.2) and then incubated at 40ºC for 30 min. Unincorporated 
111
In was purified using gel chromatography (Sephadex G-25). The labeling efficiency 
was determined by measuring the activity in dose calibrator (CRC-15R, Capintec; 
Bioscan) for the liposome, filter and supernatant.    
6.2.4 Biodistribution of [111In]-Labeled Liposome: 
Animal experiments were approved and performed according to the policies and 
guidelines of the Animal Care and Use Committee (IACUC) at Virginia Commonwealth 
University. Adult female nude mice were injected with 
111
InCl3, 
111
In-DTPA, 
111
In-
DTPA-DPPE, and 
111
In-Liposome through tail vein. The amount of radiotracer injected 
was (1.07± 0.03 MBq) in 200 µL PBS.  At different time points post injection (1hr, 6hrs, 
48hrs), mice were euthanized and key tissues were harvested. Tissues were counted in 
gamma counter and percent injected dose per gram (%ID/g) of the tissue was determined.  
6.2.5 In vivo SPECT/CT Imaging of [111In]-Labeled Liposome 
 
Micro-SPECT was performed using a multimodal (DPET/SPECT/CT) preclinical 
imaging system (Siemens, USA) having dual-head camera mounted with 2 multipinhole 
collimators (five 1.0-mm pinholes in each collimator, 51-mm trasaxial FOV, 40-mm 
radius of rotation and maximum resolution of 1.5 mm). Images were acquired over 360
o
 
in a total of 40 projections, resulting in a total imaging time of 30 min. Nude mice were 
intravenously injected with with [
111
In]-Labeled Liposomes (8MBq, 200 μL) and 2, 48, 
144 hrs later, were anesthetized with mixture of 2% isoflurane in oxygen and whole body 
micro-SPECT imaging was carried out in prone position as described above. Micro-CT 
was also performed with 75 kV and 500 μA at a resolution of 96 μm. The whole body 
scan time was 10 min. The SPECT images were reconstructed using an iterative 
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reconstruction algorithm (ordered-subset expectation maximization or OSEM3D) 
modified for the 5-pinhole geometry with a 20% energy window around the 171 keV 
photo peak of 
111
In. These images were then registered with CT images based on a 
transformation matrix previously generated using four 
57
Co landmarkers. Images were 
viewed and quantified using ASIpro, the image data analysis software. Regions of 
interest (ROIs), covering the entire organs, were drawn and the average counts were 
measured and the data was correlated to ex vivo biodistribution result from gamma 
counting. 
6.2.6 Synthesis of [18F]-FCP encapsulated [111In]-Labeled Liposomes 
 
6.2.6.1 Synthesis of [18F]-FCP 
[
18
F]-FCP was synthesized using an automated synthesis method using Allinone 
Synthesizer (Trasis, Belgium) as described previously in section 5.2.4. 
6.2.6.2 Labeled Liposome Preparation and Drug Loading 
PEGylated liposome was synthesized using the method described by Mougin-degraef et 
al[10]. Briefly, DPPC, Chol, DSPE-PEG2000, DPPE-DTPA (60:30:5:5 mole ratio) were 
mixed in 10 ml vial and dissolved with Chloroform:Methanol (CHCl3:MeOH, 9:1). The 
solvent was evaporated under rotary evaporator to form a lipid film followed by high 
vacuum to remove the residual organic solvent. Freshly synthesized [
18
F]-FCP in PBS 
was added to the lipid film and was sonicated for 10 min at 60ºC. At the end of 
sonication, the liposome solution was immediately chilled in ice. For the membrane 
radiolabeling with 
111
In, sodium acetate buffer (3M, pH 5.2) wad added to liposome 
solution. 
111
InCl3 was buffered with sodium acetate buffer (3M, pH 5.2) for 2 mins before 
incubating with buffered liposome solution at 40ºC for 30 mins. The resultant dual 
labeled liposome nanoconstruct was purified using gel chromatography (Sephadex G-
- 114 - 
 
25).The purified liposome nanoconstruct was further used for characterization and in vivo 
studies.  
6.2.6.3 Characterization 
Zeta Sizer Nano Series ZEN3600 was used to measure the hydrodynamic size and ζ 
potential of liposomes in PBS (pH~7.2). The radioactive reaction yield was calculated 
from gamma counting. The labeling and encapsulation efficiency were determined by 
counting the liposome suspension before and after chromatography on a PD-10 
(Sephadex G-25) with a dose calibrator (CRC-15R, Capintec; Bioscan). 
 
6.2. 6.4 In Vivo Dual Tracer Imaging with Trimodal PET/SPECT/CT 
Female nude hairless mice (Harlan Laboratories, USA), aged four-six weeks, innoculated 
with KB 3-1 and COLO 205 on dorsal regions on left shoulder and right flank 
respectively were employed for the in vivo imaging. [
18
F]-FCP encapsulated [
111
In]-
Labeled Liposome was administered via tail vein injection. Each mouse was injected 
with total activity of 15MBq of [
18
F]-FCP encapsulated [
111
In]-Labeled Liposome. One 
hour post administration, mice were anesthetized by Isoflurane (2.0% flow rate) and kept 
under nose cone set up for imaging. Static summed up PET image data 60 minutes post 
injection was acquired for 30 mins. At completion of the PET imaging, without moving the 
specimen, the mouse bed was moved to the SPECT/CT imaging planes. A SPECT scan was 
performed using dual-head camera mounted with 2 multipinhole collimators (five 1.0-
mm pinholes in each collimator, 51-mm trasaxial FOV, 40-mm radius of rotation and 
maximum resolution of 1.5 mm). Images were acquired over 360
o
 in a total of 40 
projections, resulting in a total imaging time of 60 mins. Micro-CT was also performed 
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with 75 kV and 500 μA at a resolution of 96 μm. The whole body scan time was 10 min 
(Fig. 23). 
After the scan, the mice were returned to the cage. The same mice were SPECT scanned 
24, 48 and 72 hours post administration. 
 
Figure 23: Sequential trimodal in vivo imaging with PET and SPECT probes was achieved through 
the above workflow. A. Injection of [
18
F]-FCP encapsulated [
111
In]-Labeled Liposomes via tail vein 
injection; B. PET imaging, C. SPECT imaging; D. X-ray CT imaging (modified from reference 
18
). 
  
 
6.2.7 Cell lines and Culture Conditions 
Human cervical carcinoma (KB-3-1) and colorectrectal adenocarcinoma (COLO-205) 
cell lines were maintained in humidified incubator at 37 °C and 5% CO2. Briefly, KB-3-1 
cells were grown in DMEM/High glucose medium supplemented with 10% fetal bovine 
serum (FBS), 5mM L-Glutamine, Penicillin (100U/ml), Streptomycin (100µg/ml) and 
Amphotericin B (0.25 ug/ml). COLO-205 cells were cultured in RPMI-1640 medium 
supplemented with 10% heat inactivated FBS Penicillin G (100U/ml), Streptomycin 
(100µg/ml) and Amphotericin B (0.25 ug/ml). The cells were grown to 70-80% 
confluency before using for the experiments.  
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6.2.8 Xenograft Animal Model 
Female athymic nude mice, (4-6 weeks old, weight: 18-25 g) were purchased from 
Harlan Laboratories, USA and provided with food and water ad libitum. Animal 
experiments were approved and performed according to the policies and guidelines of the 
Animal Care and Use Committee (IACUC) at Virginia Commonwealth University. KB-
3-1 and COLO 205 cells were cultured as mentioned above and collected for 
implantation. Tumor cells (2.5×10
6
/100µL (KB 3-1), 5.0×10
6
/100µL (COLO 205) in 
media without serum) were injected subcutaneously into the dorsal region on the right 
flank (COLO 205) and left shoulder (KB 3-1) of athymic nude mice. Following 
subcutaneous implantation digital caliper measurement of tumor size was accessed, once 
the bulge caused by the tumor growth at the injection site was visible, (approximately 5 
days). The tumor volume was calculated using the formula 0.523 × (length × width × 
thickness) and assessed thrice per week. 
 
6.3 Results 
6.3.1 [111In]-Labeled Liposome Characterization 
The mean diameter of PEGylated empty liposome was 168 nm, ζ potential was  
-2.3mV. Labeling efficiency of [
111
In]-Labeled Liposome was greater than 90%. 
6.3.2 Biodistribution Studies 
 
6.3.2.1 Biodistribution of 111InCl3 
The biodistribution study performed with 
111
InCl3 showed major accumulation of 
111
InCl3 
in liver (33.10±2.24 %ID/g) and spleen (12.35±1.82 % ID/g) at 6 hours post injection. 
The activity was subsequently cleared to (16.24±1.49 %ID/g) and (6.92±0.37% ID/g) at 
48 hours in liver and spleen respectively. However, the kidney uptake was increased with 
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time (6.86±0.60, 6 hours to 14.54±1.48%ID/g, 48 hrs) suggesting renal clearance of 
111
In 
in later time point. Data representing the biodistribution profile is demonstrated in Table 
11 and Fig. 24. 
 
Table 11: Biodistribution of tail-vein injected 
111
InCl3 (1.07± 0.03) in nude mice (n=3 per time point. 
Data are presented as %ID/g (mean±sem) values determined through gamma counting. Tissues were 
collected, weighed and gamma emission was measured in a gamma counter to calculate % ID/g 
 
Organs     1hr    6hrs   48hrs 
Blood 3.03±0.08 2.12±0.21 0.63±0.13 
Heart 1.63±0.11 1.06±0.17 1.48±0.08 
Lungs 1.93±0.12 1.93±0.27 2.21±0.01 
Liver 17.09±0.21 33.10±2.24 16.24±1.49 
Spleen 5.73±0.52 12.35±1.82 6.92±0.37 
Stomach 0.27±0.06 0.66±0.18 0.92±0.36 
Intestine 0.59±0.04 1.31±0.15 4.03±0.51 
Kidneys 4.48±0.67 6.86±0.60 14.54±1.48 
Skin 1.01±0.07 1.45±0.16 4.11±0.52 
Muscle 0.47±0.08 0.55±0.06 0.86±0.15 
Skull 1.05±0.05 1.82±0.25 4.43±2.02 
Brain 0.11±0.01 0.11±0.01 0.14±0.00 
Femur 0.75±0.12 1.50±0.42 2.04±1.26 
 
 
- 118 - 
 
 
 
Figure 24: Biodistribution of tail-vein injected 
111
InCl3 (1.07± 0.03) in nude mice (n=3 per time point. 
Data are presented as %ID/g (mean±sem) values determined through gamma counting. Tissues were 
collected, weighed and gamma emission was measured in a gamma counter to calculate %ID/g 
   
   
 
6.3.2.2 Biodistribution of [111In]-DTPA 
Table 12 and Fig. 25 show the detailed biodistribution performed in nude mice. The 
biodistribution study performed with [
111
In]-DTPA showed rapid accumulation of [
111
In]-
DTPA in kidneys (2.51±1.38 %ID/g) at 1 hour post injection. Rapid clearance from blood 
and minimal uptake was observed in other major organs. Major concentration of activity 
cleared out within an hour of administration. 
 
Table 12: Biodistribution of tail-vein injected [
111
In]-DTPA (1.07± 0.03) in nude mice (n=3 per time 
point. Data are presented as %ID/g (mean±sem) values determined through gamma counting. 
Tissues were collected, weighed and gamma emission was measured in a gamma counter to 
calculate % ID/g 
 
Organs 1hr    6hrs    48hrs 
Blood 0.06±0.02 0.00±0.00 0.00±0.00 
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Heart 0.04±0.01 0.01±0.00 0.00±0.00 
Lungs 0.12±0.02 0.03±0.00 0.01±0.00 
Liver 0.14±0.06 0.08±0.01 0.02±0.00 
Spleen 0.05±0.01 0.03±0.00 0.01±0.00 
Stomach 0.04±0.01 0.02±0.01 0.03±0.01 
Intestine 0.08±0.03 0.03±0.00 0.01±0.00 
Kidneys 2.51±1.38 0.83±0.17 0.28±0.02 
Skin 0.24±0.10 0.08±0.01 0.03±0.00 
Muscle 0.10±0.06 0.02±0.00 0.00±0.00 
Skull 0.14±0.10 0.03±0.00 0.00±0.00 
Brain 0.03±0.01 0.00±0.00 0.00±0.00 
Femur 0.14±0.06 0.01±0.00 0.00±0.00 
 
 
 
 
 
 
Figure 25: Biodistribution of tail-vein injected [
111
In]-DTPA (1.07± 0.03) in nude mice (n=3 per time 
point. Data are presented as %ID/g (mean±sem) values determined through gamma counting. 
Tissues were collected, weighed and gamma emission was measured in a gamma counter to 
calculate % ID/g 
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6.3.2.3 Biodistribution of [111In]-DTPA-DPPE 
In Table 13 and Fig. 26, the biodistribution study performed with [
111
In]-DTPA-DPPE 
lipid showed major accumulation of [
111
In]-DTPA-DPPE in liver (34.11±13.39%ID/g) and 
spleen (2.43±0.98% ID/g) at 6 hours post injection. The activity in liver declined to 
7.71±0.44%ID/g in 48 hours. However, the spleen uptake increased in later time point to 
(45.11±3.01%ID/g) 48 hours post injection. 
Table 13: Biodistribution of tail-vein injected [
111
In]-DTPA-DPPE (1.07± 0.03) in nude mice (n=3 per 
time point. Data are presented as %ID/g (mean±sem) values determined through gamma counting. 
Tissues were collected, weighed and gamma emission was measured in a gamma counter to 
calculate % ID/g 
 
Organs 1hr   6hrs   48hrs 
Blood 17.59±4.53 2.52±0.99 0.15±0.01 
Heart 3.78±0.66 1.10±0.42 0.21±0.00 
Lungs 5.66±0.77 1.69±0.67 0.34±0.00 
Liver 17.30±1.10 34.11±13.39 7.71±0.44 
Spleen 2.51±0.31 2.43±0.98 45.11±3.01 
Stomach 0.33±0.04 1.17±0.96 0.20±0.05 
Intestine 3.58±1.32 1.74±0.44 0.66±0.06 
Kidneys 3.95±0.33 1.73±0.79 0.75±0.05 
Skin 0.97±0.27 1.31±0.49 0.62±0.08 
Muscle 0.94±0.22 0.71±0.23 0.23±0.03 
Skull 1.41±0.53 0.46±0.11 0.28±0.04 
Brain 0.55±0.05 0.09±0.03 0.01±0.00 
Femur 1.08±0.20 0.68±0.37 0.63±0.10 
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Figure 26: Biodistribution of tail-vein injected [
111
In]-DTPA-DPPE (1.07± 0.03) in nude mice (n=3 
per time point. Data are presented as %ID/g (mean±sem) values determined through gamma 
counting. Tissues were collected, weighed and gamma emission was measured in a gamma counter to 
calculate % ID/g 
 
 
6.3.2.4 Biodistribution of [111In]-Labeled Liposome 
The biodistribution study performed with [
111
In]-Labeled Liposome showed significant 
RES uptake. Prominent uptake of [
111
In]-Labeled Liposome in liver and spleen was 
observed, reaching maximum levels at 6 hours of 22.86±3.86, 73.33±12.13%ID/g 
respectively which decline gradually to (7.71±0.44%ID/g) and (45.01±2.94% ID/g) in 48 
hours. Minimal uptake of [
111
In]-Labeled Liposome was observed in other major organs. 
The detailed biodistribution of [
111
In]-Labeled Liposome in normal nude mice is 
presented in Table 14 and Fig. 27.  
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Table 14: Biodistribution of tail-vein injected [
111
In]-Labeled Liposome (1.07± 0.03) in nude mice 
(n=3 per time point. Data are presented as %ID/g (mean±sem) values determined through gamma 
counting. Tissues were collected, weighed and gamma emission was measured in a gamma counter to 
calculate % ID/g 
 
 
 
 
 
 
 
 
 
 
Organs 1hr    6 hrs   48 hrs 
Blood 26.72±8.80 3.74±0.49 0.15±0.01 
Heart 5.83±0.73 1.11±0.05 0.21±0.00 
Lungs 7.63±1.01 1.97±0.20 0.34±0.00 
Liver 15.05±1.07 22.86±3.86 7.71±0.44 
Spleen 65.92±4.65 73.33±12.13 45.01±2.94 
Stomach 0.70±0.22 0.35±0.07 0.20±0.05 
Intestine 2.12±0.68 1.24±0.13 0.66±0.06 
Kidneys 4.45±0.35 1.62±0.33 0.75±0.05 
Skin 1.39±0.21 0.89±0.18 0.62±0.08 
Muscle 0.73±0.21 0.39±0.09 0.23±0.03 
Skull 3.35±0.48 0.94±0.21 0.28±0.04 
Brain 0.60±0.01 0.13±0.01 0.01±0.00 
Femur 1.28±0.10 0.99±0.18 0.6±0.10 
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Figure 27: Biodistribution of tail-vein injected [
111
In]-Labeled Liposome (1.07± 0.03) in nude mice 
(n=3 per time point. Data are presented as %ID/g (mean±sem) values determined through gamma 
counting. Tissues were collected, weighed and gamma emission was measured in a gamma counter to 
calculate % ID/g 
 
 
6.3.2.5 In vivo SPECT/CT Imaging of [111In]-Labeled Liposome 
Radiolabeled liposome (8MBq/200 µL in PBS) was injected intravenously in a female 
nude mouse (28.55gms) via tail vein injection. Imaging was carried out using 171 keV 
energy gammas 2 hours, 48 hrs and 144 hrs post injection. The resulting images are 
depicted below in Fig. 28. The images show that prominent uptake of radiotracer was in 
liver and spleen in 2 hours which corresponding to the ex vivo biodistribution data. Later 
time points show the subsequent clearance of radioactivity from spleen and liver (Fig. 29). 
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Figure 28: In vivo SPECT imaging of normal nude mice injected with [
111
In]-Labeled Liposome 
through tail vein 2, 48 and 144 hrs post injection. The images showed initial uptake of activity in RES 
and subsequent clearance with time. 
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Figure 29: The clearance profile of [
111
In]-Labeled Liposome in specific tissues as shown in SPECT 
images measured by ROI analysis.  
 
 
6.3.3 [18F]-FCP encapsulated [111In]-Labeled Liposomes 
 
6.3.3.1 Size Measurement and ζ Potential. 
Range of particle sizes was between 40 nm to 1µm with an average size of 221 nm. 
Surface charge of liposome formulation was -2.11mV. 
6.3.3.2 Entrapment and Labeling Efficiency: 
Entrapment efficiency was calculated as the percentage of liposomal encapsulated [
18
F] - 
FCP. Encapsulation efficiency of [
18
F]-FCP was 38±2 % (n=3) of the liposomal 
formulation. The surface labeling efficiency of liposome with [
111
In] was greater than 
90% after 30 mins at 40º C. 
6.3.3.3 Dual Tracer Imaging  
In vivo dual tracer imaging was carried out in KB 3-1 (sensitive) and COLO 205 
(resistant) tumor xenograft bearing nude mice following a sequential protocol as outlined 
in Fig 16 in experimental section. Sensitivity and resistance of tumor was established by 
in vitro cytotoxicity assay which was discussed in section 5.3.2. Mice received bolus 
injection of after an intravenous injection of [
18
F]-FCP encapsulated [
111
In]-Labeled 
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Liposomes. There was minimal animal manipulation because of the capability of 
automatic moving of bed between different imaging planes in trimodal system which 
conserves the full trimodal fusion. Since the dosing comes from the single nanoconstruct, 
that conserves the animal position, hence the spatial position was fixed for PET mode and 
SPECT mode. PET images acquired one hour post injection using the sequential protocol 
was automatically fused to CT. PET/CT image showed the uptake of radioactivity in RES, 
mainly liver and spleen. No bleed through of SPECT signal from 
111
In was visually noted 
in the PET images. SPECT images acquired using 171 keV γ’s from 111In one hour post 
injection was automatically fused to CT. SPECT/CT image demonstrated the 
accumulation of radioactivity in RES, mainly liver and spleen. This demonstrated the 
feasibility of dual tracer PET and SPECT imaging with [
18
F]-FCP encapsulated [
111
In]-
Labeled Liposomes using sequential protocol.  
Comparative study performed using [
18
F]-FCP alone showed the accumulation of activity 
in kidneys and bladder (Fig. 30). Activity was also seen in bone marrow, COLO 205 
tumor and KB 3-1 tumor. This implies that liposomal encapsulation of [
18
F]-FCP 
changed the pharmacokinetics of the [
18
F]-FCP by protecting it from systemic clearance 
through kidneys. 
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Figure 30: In vivo CT and PET/CT image of KB 3-1 (sensitive) and COLO 205 (resistant) tumor 
xenograft bearing nude mouse injected with 10 MBq of [
18
F]-FCP through tail vein injection 1 hour 
post administration. Image shows the uptake of [
18
F]-FCP in kidneys, bladder and marrow.  
KB 3-1(sensitive) has higher uptake than COLO205 (resistant). (A) Coronal Images (B) Volume 
Rendered Images 
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Figure 31: In vivo CT, PET/CT and SPECT/CT images of KB 3-1 (sensitive) and COLO 205 
(resistant) tumor xenograft bearing nude mouse injected with 14 MBq of [
18
F]-FCP encapsulated 
[
111
In]-Labeled Liposome through tail vein injection 1 hour post administration. PET/CT Image 
shows the uptake of [
18
F]-FCP encapsulated in [
111
In]-Labeled Liposome RES.SPECT/CT image 
shows the uptake of [
18
F]-FCP encapsulated in [
111
In]-Labeled Liposome in RES. Both image 
corresponded to each other in the uptake profile demonstrating the feasibility of dual tracer imaging 
from a single nanoconstruct. (A) Coronal Images (B) Volume Rendered Images 
 
 
6.4 Discussion:  
Pegylated liposomal nanoparticles have been used as a vehicle for therapeutic agents. As 
a therapeutic agent, liposome should carry adequate load of drug.  
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Carboplatin, a cisplatin analog, is an anticancer drug used in clinic for the treatment of 
variety of solid tumors. Although carboplatin shows comparable efficacy to cisplatin in 
ovarian, bladder and esophageal carcinomas, it has inferior efficacy in germ cell tumors, 
head and neck cancer, and lung carcinomas [14]. Carboplatin comprises as a reasonable 
alternative to cisplatin in clinic for several treatment regimes. Afforded benefit of 
carboplatin over cisplatin is due to its toxicity profile. Carboplatin shows less 
nephrotoxicity, neurotoxicity and ototoxicity than cisplatin. However, myelosuppression 
is a dose limiting factor for cisplatin.  
Resistance to platinum drug remains a huge obstacle in platinum therapy. Carboplatin 
resistance arises from reduced concentration of carboplatin reaching the tumor, increased 
efflux, intracellular detoxification by glutathione, increased DNA repair, decreased 
mismatch repair, defective apoptosis, and impairment in various signaling pathways [15]. 
Development of new platinum derivatives is prompted with an aim to deliver higher 
amount of platinum drugs to tumor and modulate the interaction with the DNA to 
overcome the resistance. 
We addressed some of those limitations of platinum therapy by synthesizing a novel 
carboplatin derivative with non invasive imaging capability. We further extended the 
work by developing a radiolabeled liposomal formulation of the novel drug and 
investigated its in vivo pharmacokinetics using multimodal imaging. This study 
demonstrates the feasibility of optimal radiolabeling the DTPA-derivatized pegylated 
liposomes with 
111
In. Detailed in vivo biodistribution of [
111
In]-Labeled Liposome 
contrast directly with the behavior of the components of liposome. [
111
In]-DTPA cleared 
very rapidly from the circulation with most activity observed in kidneys suggesting renal 
- 130 - 
 
clearance which agrees to the data published by Harrington et al [6]. Pharmacokinetic 
profile of [
111
In]-Labeled Liposome showed major uptake in RES. Major uptake was 
observed in spleen and liver. Gradual accumulation of radioactivity was observed in 
spleen with highest uptake (73.33±12.13 % ID/g) in six hours. Minimal accumulation of 
radioactivity was observed in other major organs. Subsequent clearance of radioactivity 
with time was observed in all organs. Feasibility of SPECT imaging with  
[
111
In]-Labeled Liposome was demonstrated (Fig. 28). Images showed the initial 
accumulation of activity in liver and spleen which corresponds to the ex vivo 
biodistribution data. Extended imaging with [
111
In]-Labeled Liposome was enabled 
because of the medium half life of 
111
In (t1/2= 2.8 days). Images during later time points 
(48, 144 hours) showed the gradual clearance of activity from liver and spleen. In vivo 
biodistribution studies performed with various components of liposomes enabled 
comparative interpretation of [
111
In]-Labeled Liposome with other components. 
[
18
F]-FCP was encapsulated into [
111
In]-Labeled Liposome via passive encapsulation 
method. Encapsulation efficacy was 38% which was slightly higher than the values 
reported in the literature [16, 17]. Surface labeling with 
111
In was greater than 90% which 
agrees to the value reported in literature [13].  
Multimodal imaging has been very useful for researchers for a range of in vivo study. 
Single modality imaging such as SPECT, PET has been intensively used to gather in vivo 
functional data. Complexity of disease state and the unique pathways they express may 
not be easily visible for a single modality. Therefore, dual modality imaging further 
strengthens the capacity to gather robust data and can image different pathways 
simultaneously/sequentially which is otherwise not possible with a single modality. 
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Various researchers have presented dual modality imaging with combination of reporters 
and tracers. However, there are very few studies that combine two PET and SPECT 
radiotracers in a single nanoparticle. Chapman et al [18] demonstrated the dual tracer 
imaging feasibility of SPECT and PET probes in living mice using a sequential protocol. 
As part of the dosing protocol in the study Chapman et al injected SPECT tracer at first 
and acquired the SPECT images and injected the PET tracer after the SPECT scan is 
performed. Mastunari et al [19] studied the detection of viable myocardium using dual 
isotope simultaneous acquisition SPECT using [
18
F]-FDG and 99mTc-sestamibi. To our 
knowledge, there is no study that performs the dual tracer PET/SPECT imaging from a 
radiolabeled drug encapsulated nanoparticle. In this study, we have demonstrated the 
feasibility of dual tracer sequential imaging with PET and SPECT using [
18
F]-FCP 
encapsulated [
111
In]-Labeled Liposome (Fig. 31). [
18
F]-FCP encapsulated [
111
In]-Labeled 
Liposome showed major uptake in RES in both PET and SPECT images. ROI analysis of 
SPECT image enabled by 
111
In corresponded with PET image enabled by 
18
F 
demonstrating the feasibility of dual tracer imaging from the single nanoconstruct. From 
our previous study with [
111
In]-Labeled Liposome we observed the uptake of liposome in 
RES which is propagated in PET and SPECT images acquired from [
18
F]-FCP 
encapsulated [
111
In]-Labeled Liposome in an hour after administration. This suggests that 
the [
18
F]-FCP is intact with [
111
In]-Labeled Liposome. Comparison of PET images 
acquired with [
18
F]-FCP alone (Fig. 30) and PET and SPECT images acquired with [
18
F]-
FCP is intact with [
111
In]-Labeled Liposome showed different pharmacokinetic profiles. 
One important finding of this study was [
18
F]-FCP uptake in KB 3-1 (sensitive) tumor 
was higher than COLO205 (resistant) tumor within an hour post intravenous 
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administration. The uptake of [
18
F]-FCP encapsulated [
111
In]-Labeled Liposome was not 
visible in tumors within an hour post intravenous injection. This can be attributed to the 
duration needed for the passive accumulation of liposome through EPR effect in tumors. 
Liposomal formulation of [
18
F]-FCP changed the pharmacokinetics of carboplatin 
derivative. However, detailed in vivo evaluation using different mouse models and 
biodistribution studies is required to confirm the behavior of [
18
F]-FCP encapsulated 
[
111
In]-Labeled Liposome. 
6.5 Conclusion 
DTPA-derivatized pegylated liposome was labeled with 
111
In. [
111
In]-Labeled Liposome 
was evaluated in vivo with biodistribution and SPECT imaging. [
18
F]-FCP was 
encapsulated in [
111
In]-Labeled Liposome. Dual tracer feasibility of PET/SPECT imaging 
with [
18
F]-FCP was encapsulated in [
111
In]-Labeled Liposome was demonstrated. 
Different pharmacokinetic profile of [
18
F]-FCP alone and its liposomal encapsulation in 
[
111
In]-Labeled Liposome was shown in tumor xenograft bearing nude mice. 
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 CHAPTER 7: CONCLUSION AND FUTURE WORK 
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7.1 Summary of Conclusion 
Radiolabeled carboplatin derivative [
18
F]-FCP has been synthesized with 
18
F as a 
molecular imaging entity for the first time using malonic acid derivative. Manual 
synthesis of [
18
F]-FCP was optimized using low scale of activity. Purification of [
18
F]-
FCP was optimized using anion exchange method. Automated synthesis of [
18
F]-FCP 
using radio synthesizer was optimized using the manual synthetic procedure and inserting 
them as macros for sequences. The radiochemical purity was characterized using radio-
HPLC. Feasibility of in-vivo PET imaging of [
18
F]-FCP was demonstrated in normal and 
KB3-1 and KB8-5 tumor xenograft bearing nude mice. In vivo plasma and urine stability 
test confirmed the intact [
18
F]-FCP after intravenous administration. Detailed 
biodistribution in various tissues of [
18
F]-FCP was performed in normal nude mice. 
 
Radiolabeled Pegylated [
111
In]-Labeled Liposome has been synthesized as a nanodrug 
delivery vehicle. Labeling efficiency was determined. The physiochemical characteristics, 
hydrodynamic size and zeta potential, were assessed using DLS. Feasibility of in vivo 
SPECT imaging with [
111
In]-Labeled Liposome was demonstrated. Detailed 
biodistribution of [
111
In]-labeled Liposome in various tissues was performed in normal 
nude mice. Comparative evaluation of tissue distribution of [
111
In]-labeled Liposome 
with 
111
InCl3, [
111
In]-DTPA-DPPE, and [
111
In]-DTPA was performed to determine the 
pharmacokinetic profiles of different components of liposome. 
 
Finally, [
18
F]-FCP encapsulated [
111
In]-Labeled Liposome; a dual labeled nanoconstruct, 
capable of providing two distinct PET and SPECT signals from a single nanoconstruct 
was developed. The physiochemical characteristics including size and zeta potential of 
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[
18
F]-FCP encapsulated [
111
In]-Labeled Liposome were assessed with DLS. Entrapment 
efficiency of [
18
F]-FCP, labeling efficiency of 
111
InCl3
 
were determined. In vivo PET 
imaging using [
18
F]-FCP alone was performed in KB 3-1 and COLO 205 tumor xenograft 
bearing nude mice. Feasibility of dual tracer PET/SPECT imaging from a single 
nanoconstruct was demonstrated in KB 3-1 and COLO 205 tumor xenograft bearing nude 
mice. Comparison of pharmacokinetic profile of naked [
18
F]-FCP with [
18
F]-FCP 
encapsulated [
111
In]-Labeled Liposome demonstrated different routes of elimination of 
radiotracers. 
7.2 Future Work 
This is an ongoing work. The demonstration of dual tracer imaging feasibility of [
18
F]-
FCP encapsulated [
111
In]-Labeled Liposome establishes the proof of concept of liposomal 
formulation of a novel platinum derivative. However, this study did not address the 
intensive in vitro characterization of [
18
F]-FCP encapsulated [
111
In]-Labeled Liposome. 
In vitro characterization such as plasma binding with naked [
18
F]-FCP, [
111
In]-Labeled 
Liposome and [
18
F]-FCP encapsulated [
111
In]-Labeled Liposome needs to be established 
to get a detail understanding of the in vivo properties of [
18
F]-FCP encapsulated [
111
In]-
Labeled Liposome. Detail biodistribution studies of [
18
F]-FCP encapsulated [
111
In]-
Labeled Liposome in normal and tumor xenograft bearing mice remains to be 
accomplished. Biodistribution study will demonstrate the pharmacokinetic behavior of 
[
18
F]-FCP encapsulated [
111
In]-Labeled Liposome. The information gathered from this 
will help interpret the behavior of the nanoconstruct which can further be compared with 
[
111
In]-Labeled Liposome alone and [
18
F]-FCP alone. Several factors must be considered 
when using a dual tracer probe for an optimal in vivo imaging. Relative properties of each 
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radionuclide and its contribution to each modality must be configured before imaging. 
Although it is likely that PET detection of [
18
F]-FCP excludes [
111
In]-Labeled 
Liposome’s 171 keV energy, potential cross talk between [18F]-FCP into the SPECT 
acquisition energy window and [
111
In]-Labeled Liposome into the PET acquisition must 
be validated by phantom experiments. 
The development of fluorinated carboplatin derivative lends a feasible platform for 
developing radiolabeled platinum derivatives with other isotopes. [
18
F]-FCP enables PET 
imaging, a non invasive imaging technology that can be exploited to study the in vivo 
pharmacokinetics of drug. Information such as drug distribution, drug ability for blood 
brain barrier penetration, bioavailability and tissue concentration and clearance of drug 
can be achieved by radiolabeled drug and non invasive imaging. 
18
F is a positron emitter 
with a half life of 110 mins. Due to the short half life of 
18
F, [
18
F]-FCP enables in vivo 
pharmacokinetic studies for a short duration of time. Iodine-124 (
124
I) is an isotope of 
iodine with a half life of 4.18 days. Its modes of decay are: 74.4% EC and 25.6% positron 
emission (β+). Feasibility of production of 124I using a cyclotron offers an advantage 
because of the availability of cyclotron on site at VCU. Developing an [
124
I]- labeled 
carboplatin derivative using malonic acid derivative will enable in vivo PET imaging and 
prolonged in vivo pharmacokinetic study which is otherwise difficult with [
18
F]-FCP. 
Furthermore, encapsulation of [
124
I]-labeled carboplatin derivative inside [
111
In]-Labeled 
Liposome will enable dual tracer imaging using PET/SPECT. Liposomal formulation will 
change the pharmacokinetic profile of the drug and reduces the exposure of naked drug, 
hence less normal tissue toxicity and increased bioavailability. The medium half lives of 
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both isotopes (2.8 days of 
111
In, 4.8 days of 
124
I), enable prolonged in vivo study of the 
liposomal formulation using non invasive imaging. 
In vivo therapeutic merit of 
19
F-FCP in comparison of parent compound needs to be 
demonstrated. Evaluation of the nephrotoxicity of 
19
F-FCP in comparison with its 
encapsulated formulation and the parent compound needs to be accomplished. 
Modulation of nephrotoxicity by nanoparticle free radical scavengers such as nanoceria 
should be investigated. 
Developing [
18
F]-FCP, [
124
I]-labeled carboplatin derivative using an isotope of platinum, 
195m
Pt (half life 4.0 days, energy released from Auger electrons 23keV/decay) would 
enable dual therapy, cytotoxic and radiotherapy from the same platinum compound. This 
approach of dual therapy from Pt isotope with a molecular imaging entity attached to the 
radiopharmaceutical would provide theranostic and synergistic effect in cancer therapy and 
provide a platform in optimizing the response of therapy to treatment.  
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